    		                		            		                                                                                                                                          	    		   		   	  	       	            							    	    																																			    																	    	    	                             		       	                                                                                                   	        						    	    																																			    																	    	    	                             		       	                                                                                               									    	    																																			    																	    	    	                             		       	                                                                                               									    	    																																			    																	    	    	                             		       	                                                                                               	            			        	                            						    	    																																			    																	    	    	                             		       	                                                                                                                                                                                                                                                                                                                       	     <!DOCTYPE html><html><head><script id="f5_cspm">(function(){var f5_cspm={f5_p:'MAGENAKOEAEHCPGCIDPEGLJBKBCBGGDHEOAMDABONOGBCEEPOAANNOBMDOHADGOLHDFOBBFNFEOCMBJPCHKKKKALGNBOINGFNMCPCIEOJMBAFMFFAFONOKKMCOKBINFO',setCharAt:function(str,index,chr){if(index>str.length-1)return str;return str.substr(0,index)+chr+str.substr(index+1);},get_byte:function(str,i){var s=(i/16)|0;i=(i&15);s=s*32;return((str.charCodeAt(i+16+s)-65)<<4)|(str.charCodeAt(i+s)-65);},set_byte:function(str,i,b){var s=(i/16)|0;i=(i&15);s=s*32;str=f5_cspm.setCharAt(str,(i+16+s),String.fromCharCode((b>>4)+65));str=f5_cspm.setCharAt(str,(i+s),String.fromCharCode((b&15)+65));return str;},set_latency:function(str,latency){latency=latency&0xffff;str=f5_cspm.set_byte(str,32,(latency>>8));str=f5_cspm.set_byte(str,33,(latency&0xff));str=f5_cspm.set_byte(str,27,2);return str;},wait_perf_data:function(){try{var wp=window.performance.timing;if(wp.loadEventEnd>0){var res=wp.loadEventEnd-wp.navigationStart;if(res<60001){var cookie_val=f5_cspm.set_latency(f5_cspm.f5_p,res);window.document.cookie='aaaaaaaaaaaaaaa='+encodeURIComponent(cookie_val)+';path=/';}return;}}catch(err){return;}setTimeout(f5_cspm.wait_perf_data,100);return;},go:function(){var chunk=window.document.cookie.split(/\s*;\s*/);for(var i=0;i<chunk.length;++i){var pair=chunk[i].split(/\s*=\s*/);if(pair[0]=='f5_cspm'){if(pair[1]=='1234'){var d=new Date();d.setTime(d.getTime()-1);window.document.cookie='f5_cspm=;expires='+d.toUTCString()+';path=/;';setTimeout(f5_cspm.wait_perf_data,100);}}}}}f5_cspm.go();}());</script>        	<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" />    <meta charset="utf-8" />        	<title>DailyMed - CELEXA- citalopram hydrobromide tablet, film coated  </title>                <!--[if lt IE 9]>        <script src="//html5shim.googlecode.com/svn/trunk/html5.js"></script>    <![endif]-->    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/skeleton.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/jquery.jqzoom.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/style.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/header-search.min.css" />    <link rel="stylesheet" type="text/css" media="all" href="dailymed/css/responsive.min.css" />    <link rel="stylesheet" type="text/css" media="print" href="dailymed/css/print.min.css" />    <!--[if !IE]><!-->    <link rel="stylesheet" type="text/css" media="all" href="dailymed/css/responsive-tables.min.css" />    <!--<![endif]-->    <link rel="icon" href="dailymed/images/favicons/favicon.ico" type="image/x-icon" />    <link rel="shortcut icon" href="dailymed/images/favicons/favicon.ico" type="image/x-icon"/>        <link rel="apple-touch-icon" sizes="57x57" href="dailymed/images/favicons/apple-touch-icon-57x57.png">    <link rel="apple-touch-icon" sizes="114x114" href="dailymed/images/favicons/apple-touch-icon-114x114.png">    <link rel="apple-touch-icon" sizes="72x72" href="dailymed/images/favicons/apple-touch-icon-72x72.png">    <link rel="apple-touch-icon" sizes="144x144" href="dailymed/images/favicons/apple-touch-icon-144x144.png">    <link rel="apple-touch-icon" sizes="60x60" href="dailymed/images/favicons/apple-touch-icon-60x60.png">    <link rel="apple-touch-icon" sizes="120x120" href="dailymed/images/favicons/apple-touch-icon-120x120.png">    <link rel="apple-touch-icon" sizes="76x76" href="dailymed/images/favicons/apple-touch-icon-76x76.png">    <link rel="apple-touch-icon" sizes="152x152" href="dailymed/images/favicons/apple-touch-icon-152x152.png">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-196x196.png" sizes="196x196">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-160x160.png" sizes="160x160">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-96x96.png" sizes="96x96">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-16x16.png" sizes="16x16">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-32x32.png" sizes="32x32">    <meta name="msapplication-config" content="/dailymed/images/favicons/browserconfig.xml" />    <meta name="msapplication-TileColor" content="#da532c">    <meta name="msapplication-TileImage" content="/dailymed/images/favicons/mstile-144x144.png">    <meta name="description" content="" />    <meta name="keywords" content="" />     <meta name="robots" content="noimageindex, noodp, noydir" />     <meta name="viewport" id="viewport" content="width=device-width,minimum-scale=1.0,maximum-scale=10.0,initial-scale=1.0" />    <script src="/dailymed/scripts/modernizr-2.0.6.min.js"></script>        <script type="text/javascript" src="//ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js"></script>        <script type="text/javascript">        if (typeof jQuery == 'undefined')        {              document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-1.10.2.min.js">\x3C/script>');        }    </script>                	                	            	    	<script type="text/javascript">		var basepath = "/dailymed";;		var availableClasses =  new Array();;		for(var i = 0; i < availableClasses.length; i++){			availableClasses[i] = availableClasses[i].replace(/"/g, '').trim();		}		var labeltitle = "CELEXA- citalopram hydrobromide tablet, film coated <br>";;		var emailLink = "";;		var emailrequest = "0";;	</script>    <script src="/dailymed/scripts/javascript-html-attribute-encoding.min.js"></script>	<script src="/dailymed/scripts/scripts.min.js"></script>        <script type='text/javascript' src="//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/jquery-ui.min.js"></script>    <script type="text/javascript">        if (typeof jQuery.ui == 'undefined')        {            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-ui-1.10.4.custom.min.js">\x3C/script>');            document.write('\x3Clink rel="stylesheet" type="text/css" media="all" href="dailymed/css/jquery-ui-1.10.4.custom.min.css">');        }        else{            document.write('<link rel="stylesheet" href="/ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/themes/smoothness/jquery-ui.min.css">');        }    </script>    <script type='text/javascript' src='/dailymed/scripts/jquery.elevateZoom-3.0.8.min.js'></script>      <script type="text/javascript" src="/dailymed/scripts/jquery.placeholder.min.js"></script>    <script src="//www.accessdata.fda.gov/spl/stylesheet/spl.js" type="text/javascript" charset="utf-8">/* */</script>    <!-- Magnific Popup core CSS file -->    <link rel="stylesheet" href="dailymed/css/magnific-popup.min.css">        <!-- Magnific Popup core JS file -->    <script src="/dailymed/scripts/jquery.magnific-popup.js"></script>        <meta name = "format-detection" content = "telephone=no"></head><body class="inner drug-info">	<div class="container_1000 bg_shadow">        <div style="width: 0; height: 0;"><a href="#" id="top-of-page"></a></div><header>	<div class="topHeader">				<ul id="skip">		<li><a href="#skip-main-content">Skip to Main Content</a></li></ul>		<nav class="topHeaderNav">        	<div class="topNIHLogo mobileview">        		<a href="http://www.nih.gov" class="top-logo" title="National Institutes of Health" target="_blank"><img src="/dailymed/images/nih-toplogo.png" alt="NIH Logo"/></a>            	<a href="/www.nlm.nih.gov" title="U.S. National Library of Medicine" target="_blank">U.S. National Library of Medicine</a></div>			<div class="container">				<div class="sixteen columns">                	<div class="topNIHLogo"><a href="http://www.nih.gov" title="National Institutes of Health" target="_blank"><img src="/dailymed/images/nih-toplogo.png" alt="NIH Logo"/></a>                    <a href="/www.nlm.nih.gov" title="U.S. National Library of Medicine" target="_blank">U.S. National Library of Medicine</a></div>					<ul>																		<li class="safety"><a title="Report Adverse Events" href="/www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report Adverse Events </a><span>|</span><a title="FDA Safety Reporting and Recalls" href="http://www.fda.gov/Safety/Recalls" target="_blank">Recalls</a></li>					</ul>				</div>			</div>		</nav>		<div class="divider"></div>	</div>	<div class="dailymedlogoprint"><img src="/dailymed/images/logo.png" alt="DailyMed" /></div>	<div class="bottomHeader">		<div class="header-image">						<div class="mobile-menu-btn closed hasjs" tabindex="0"></div><div class="mobile-menu">		<div class="mobile-menu-container">		<div class="pro-menu active">			<div class="first half">				<ul>					<li><a href="dailymed/index.cfm">Home</a></li>					<li>						News						<ul>							<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>							<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>						</ul>					</li>					<li><a href="dailymed/about-dailymed.cfm">About Dailymed</a></li>					<li><a href="dailymed/contact-us.cfm">Contact Us</a></li>					<li>						Safety Reporting &amp; Recalls						<ul>							<li><a href="/www.accessdata.fda.gov/scripts/medwatch/">Report Adverse Events</a></li>							<li><a href="http://www.fda.gov/Safety/Recalls">FDA Saftey Recalls</a></li>						</ul>					</li>					<li>						<a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a>											</li>				</ul>			</div>			<div class="last half">				<ul>					<li>						NLM SPL Resources						<ul>							<li>								<a href="dailymed/spl-resources.cfm">Download Data</a>								<ul>									<li><a href="dailymed/spl-resources-all-drug-labels.cfm">- All Drug Labels</a></li>									<li><a href="dailymed/spl-resources-all-indexing-files.cfm">- All Indexing Files</a></li>									<li><a href="dailymed/spl-resources-all-mapping-files.cfm">- All Mapping Files</a></li>								</ul>							</li>							<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>							<li><a href="dailymed/spl-resources-all-mapping-files.cfm">Articles &amp; Presentations</a></li>						</ul>					</li>					<li>						Application Development Support						<ul>							<li>								<a href="dailymed/app-support.cfm">Resources</a>								<ul>									<li><a href="dailymed/app-support-web-services.cfm">- Web Services</a></li>																		<li><a href="dailymed/app-support-mapping-files.cfm">- Mapping Files</a></li>								</ul>							</li>						</ul>					</li>					<li><a href="dailymed/help.cfm">Help</a></li>				</ul>			</div>		</div>			</div></div>			<a href="dailymed/index.cfm" class="logo" title="DailyMed">DailyMed</a>						<div class="header-search-container">				<div id="header-search">									    					    				    <form action="/dailymed/search.cfm">		<div class="searchNav">		<ul class="searchType">			<li class="all active">									<input type="radio" class="hidden" name="labeltype" id="labeltype-all" value="all" />					<label for="labeltype-all">All Drugs</label>							</li>			<li class="human">									<input type="radio" class="hidden" name="labeltype" id="labeltype-human" value="human"/>					<label for="labeltype-human">Human Drugs</label>							</li>			<li class="animal">									<input type="radio" class="hidden" name="labeltype" id="labeltype-animal" value="animal" />					<label for="labeltype-animal">Animal Drugs</label>							</li>							<li class="more-ways" id="header-search-more-ways">					<a href="#" id="more-ways-button" class="more-ways-label">More ways to search</a>					<ul id="more-ways-dropdown" class="dropdown" style="display:none;">						<li>							<a href="dailymed/advanced-search.cfm">Advanced Search</a>						</li>						<li>							<a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a>						</li>						<li>							<a href="dailymed/archives/index.cfm">Label Archives</a>						</li>						<li>							<a class="external-link" href="http://pillbox.nlm.nih.gov" target="_blank">Tablet/Capsule ID Tool</a>						</li>					</ul>				</li>								</ul>	</div>			<div class="searchForm">					<div class="searchInput">				<input id="searchQuery" name="query" tabindex="0" type="text" placeholder="Enter drug, NDC code, drug class, or Set ID" autocorrect="off" autocapitalize="off">									<button class="search-button">  </button>							</div>								<input class="search" tabindex="0" title="Search" type="submit" value="Search">	</div></form>									</div>			</div>			<div class="mobile-search-btn" tabindex="0"></div>												<div class="header-bg">																										</div>			<div class="divider"></div>		</div>		<div class="bottomHeaderContent">									<div class="search mobile-search">				<div class="divider_10 nomargin mobileview"></div>				<div class="searchTool mobileview"></div>															<form action="/dailymed/search.cfm">		<div class="searchNav">		<ul class="searchType">			<li class="all active">									<input type="radio" class="hidden" name="labeltype" id="labeltype-all-2" value="all" />					<label for="labeltype-all-2">All Drugs</label>							</li>			<li class="human">									<input type="radio" class="hidden" name="labeltype" id="labeltype-human-2" value="human"/>					<label for="labeltype-human-2">Human Drugs</label>							</li>			<li class="animal">									<input type="radio" class="hidden"  name="labeltype" id="labeltype-animal-2" value="animal" />					<label for="labeltype-animal-2">Animal Drugs</label>							</li>								</ul>	</div>			<div class="searchForm">					<div class="searchInput">				<input id="searchToolsQuery" name="query" tabindex="0" type="text" placeholder="Enter drug, NDC code, drug class, or Set ID" autocorrect="off" autocapitalize="off">			</div>								<input class="search" tabindex="0" title="Search" type="submit" value="Search">	</div></form>								<div class="divider"></div>								<nav class="bottomHeaderNav">                <noscript>                <div class="tabletnav no-js">                    <div class="col">                        <ul>                            <li><a href="dailymed/index.cfm">Home</a></li>                            <li>News                                <ul>                                    <li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>                                    <li><a href="dailymed/rss-updates.cfm">Get RSS News & Updates</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li>Search                                <ul>                                    <li><a href="dailymed/advanced-search.cfm">Advanced Search</a></li>                                    <li><a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>                                    <li><a href="dailymed/archives/index.cfm">Labels Archives</a></li>                                                                        <li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID Tool</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li><a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a></li>                            <li>NLM SPL Resources                                <ul>                                    <li><a href="dailymed/spl-resources.cfm">Download Data</a>                                        <ul>                                            <li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>                                            <li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Index Files</a></li>                                            <li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>                                        </ul>                                    </li>                                    <li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>                                    <li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li>Application Development Support                                <ul>                                    <li><a href="dailymed/app-support.cfm">Resources</a>                                        <ul>                                            <li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>                                            <li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>                                        </ul>                                    </li>                                </ul>                            </li>                            <li><a href="dailymed/help.cfm">Help</a></li>                        </ul>                    </div>                </div>           		</noscript>                					<ul class="webview hasjs">						<li><a href="dailymed/index.cfm" title="Home">Home</a></li>						<li>													<a href="#" title="News">												News</a>							<ul class="sub-menu">								<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>								<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>							</ul>						</li>						<li>																				<a href="dailymed/fda-drug-guidance.cfm" title="FDA Guidances &amp; Info">												FDA Guidances &amp; Info</a>													</li>						<li>													<a href="#" title="Structured Product Labeling (SPL) resources for industry professionals.">												NLM SPL Resources</a>														<ul class="sub-menu">								<li><a href="dailymed/spl-resources.cfm">Download Data</a>									<ul>										<li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>										<li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Indexing Files</a></li>										<li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>									</ul>								</li>								<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>								<li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>							</ul>						</li>						<li>													<a href="#" title="Application Development Support">												Application Development Support</a>							<ul class="sub-menu">								<li><a href="dailymed/app-support.cfm">Resources</a>									<ul>										<li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>																				<li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>									</ul>								</li>							</ul>						</li>									  						<li>													<a href="dailymed/help.cfm" title="Help">												Help</a></li>   					</ul>					<ul class="tabletview hasjs">						<li><a href="dailymed/advanced-search.cfm" title="Advanced Search">Advanced Search</a></li>						<li class="viewmore"><a href="#" title="View More">View More</a>							<ul>								<li><span>News</span>									<ul>										<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>										<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>									</ul>								</li>								<li><span>Safety Reporting and Recalls</span>									<ul>										<li><a href="/www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report Adverse Events</a></li>										<li><a href="/www.fda.gov/Safety/Recalls" target="_blank">FDA Saftey Recalls</a></li>									</ul>								</li>								<li>									<a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a>								</li>																<li><span>NLM SPL Resources</span>									<ul>										<li><a href="dailymed/spl-resources.cfm">Download Data</a>											<ul>												<li><a href="dailymed/spl-resources-all-drug-labels.cfm">- All Drug Labels</a></li>												<li><a href="dailymed/spl-resources-all-indexing-files.cfm">- All Indexing Files</a></li>												<li><a href="dailymed/spl-resources-all-mapping-files.cfm">- All Mapping Files</a></li>											</ul>										</li>										<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>										<li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>									</ul>								</li>   								<li><span>Application Development Support</span>									<ul>										<li><a href="dailymed/app-support.cfm">Resources</a>											<ul>												<li><a href="dailymed/app-support-web-services.cfm">- Web Services</a></li>																								<li><a href="dailymed/app-support-mapping-files.cfm">- Mapping Files</a></li>											</ul>										</li>									</ul>								</li>   								<li><a href="dailymed/help.cfm" title="Help">Help</a></li>   							</ul>						</li>						<li class="mobileview viewmore" tabindex="0"><a title="View More" href="#">More ways to search</a>							<ul>								<li tabindex="0"><a title="Browse Drug Classes" href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>								<li tabindex="0"><a title="Label Archives" href="dailymed/archives/index.cfm">Label Archives</a></li>																<li tabindex="0"><a target="_blank" title="Tablet/Capsule ID Tool" href="http://pillbox.nlm.nih.gov/">Tablet/Capsule ID Tool</a></li>   							</ul>						</li>					</ul>										<ul class="mobileview hasjs">						<li><a href="dailymed/advanced-search.cfm" title="Advanced Search">Advanced Search</a></li>						<li tabindex="0" class="viewmore"><a href="#" title="View More">View More</a>							<ul>								<li tabindex="0"><a href="dailymed/browse-drug-classes.cfm" title="Browse Drug Classes">Browse Drug Classes</a></li>								<li tabindex="0"><a href="dailymed/archives/index.cfm" title="Label Archives">Label Archives</a></li>																<li tabindex="0"><a href="http://pillbox.nlm.nih.gov/" title="Tablet/Capsule ID Tool" target="_blank">Tablet/Capsule ID Tool</a></li>   							</ul>						</li>					</ul>				</nav>				<div class="divider_10 nomargin"></div>			</div>					</div>				<div class="divider"></div>	</div></header><div id="skip-main-content"></div>        <div class="container">             <div class="main-content">                <div class="header long">                    <div class="header-top">                            <h1>Label: <span class="long-title">CELEXA- citalopram hydrobromide tablet, film coated <br></span></h1>                    </div>                                        <ul class="tools">                    	                        <li class="rss"><a href="#modal-label-rss" class="modal-open">Label RSS</a></li>                        <li class="share">Share                            <noscript>: JavaScript needed for Sharing tools</noscript>                            <!-- AddThis Button BEGIN -->                            <div class="addthis_toolbox addthis_default_style addthis_16x16_style">                                                                                                    	                                	            			        	                                                            <a class="email-share" href="mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0ACELEXA%2D%20Citalopram%20Hydrobromide%20Tablet%2C%20Film%20Coated%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3D4259d9b1%2Dde34%2D43a4%2D85a8%2D41dd214e9177%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E" title="Share by Email"></a>                                <a class="addthis_button_facebook"></a>                                <a class="addthis_button_twitter"></a>                                                                <a class="at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share" href="/www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed" target="_blank" style="display: block;">                                    <span style="left: -9999px; position: absolute;">Bookmark &amp; Share</span><img style="width:17px" src="/dailymed/images/addthis-image.jpg"></img>                                </a>                            </div>                            <script type="text/javascript">var addthis_config = {"data_track_addressbar":false};</script>                            <script type="text/javascript" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5" ></script>                             <!-- AddThis Button END -->                                                    </li>                    </ul>                  </div>                <div class="four columns sidebar" id="leftmenu">                    <section>                        <article>                                                        <div class="w-photos">                            	                                                                <div class="mod drug-photos">                                <h2><a>View Package Photos</a></h2>                                <ul>                                    <li>                                                                               <ul>                                                                                                                        	                                            	 <li class="img package-photo"><a href="image.cfm?type=img&name=cel00-0019-02.jpg&setid=4259d9b1-de34-43a4-85a8-41dd214e9177" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="0">                                                 	<img id="zoom_1" title="Package Photo" alt="Package Photo"                                                     data-zoom-image="image.cfm?type=img&name=cel00-0019-02.jpg&setid=4259d9b1-de34-43a4-85a8-41dd214e9177" src="image.cfm?type=img&name=cel00-0019-02.jpg&setid=4259d9b1-de34-43a4-85a8-41dd214e9177" data-photo-type="package">                                                 	<span class="enlarge"></span>                                                    </a></li>                                                                                             											                                                                                	                                            	 <li class="img package-photo"><a href="image.cfm?type=img&name=cel00-0019-03.jpg&setid=4259d9b1-de34-43a4-85a8-41dd214e9177" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="1">                                                 	<img id="zoom_2" title="Package Photo" alt="Package Photo"                                                     data-zoom-image="image.cfm?type=img&name=cel00-0019-03.jpg&setid=4259d9b1-de34-43a4-85a8-41dd214e9177" src="image.cfm?type=img&name=cel00-0019-03.jpg&setid=4259d9b1-de34-43a4-85a8-41dd214e9177" data-photo-type="package">                                                 	<span class="enlarge"></span>                                                    </a></li>                                                                                             											                                                                                </ul>                                    </li>                                </ul>								                                    <h4 class="more closed">VIEW MORE</h4>                                        <div class="show-more">                                            <ul>                                                                                                                        <li>                                                <ul>                                                                                    <li class="img package-photo">                                            	<a href="image.cfm?type=img&name=cel00-0019-04.jpg&setid=4259d9b1-de34-43a4-85a8-41dd214e9177" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="2">                                                <img id="zoom_3" title="Package Photo" alt="Package Photo"                                                 data-zoom-image="image.cfm?type=img&name=cel00-0019-04.jpg&setid=4259d9b1-de34-43a4-85a8-41dd214e9177" src="image.cfm?type=img&name=cel00-0019-04.jpg&setid=4259d9b1-de34-43a4-85a8-41dd214e9177" data-photo-type="package">                                                <span class="enlarge"></span>                                                </a></li>                                                                                         </ul>                                             </li>                                                                                                                                                            </ul>                                     </div>                                                                 </div>            								                                                                                            </div>                            <div class="mod-wrap">                                <div class="mod blue-list page-jump">                                    <h2><a href="#drug-information">Drug Label Info</a></h2>                                </div>                                                                <div class="mod blue-list orange">                                                                                                                                                                                                                                                                                                                                                                            <h2><a href="#">Safety</a></h2>                                    <ul>                                                                                    <li>                                                <a class="tip" rel="tooltip" title="A boxed warning is the strongest warning that the FDA requires, and signifies that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects." href="#boxedwarning">Boxed Warnings</a>                                            </li>                                                                                                                                                                    <li>                                                <a href="/www.accessdata.fda.gov/scripts/medwatch/ " target="_blank">Report Adverse Events</a>                                            </li>                                            <li><a href="http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety Recalls</a></li>                                            <li>                                                <a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22citalopram%22+%29" target="_blank">Presence in Breast Milk</a>                                            </li>                                                                            </ul>                                </div>                                <div class="mod blue-list">                                    <h2><a href="#">Related Resources</a></h2>                                    <ul>                                                                                                                            <li>                                                <a href="/vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&query=citalopram" target="_blank">Medline Plus</a>                                            </li>                                                                                <li>                                            <a href="/www.clinicaltrials.gov/ct/search?submit=Search&term=citalopram" target="blank">Clinical Trials</a>                                        </li>                                                                                    <li>                                                <a href="#" id="pubmed-menu">PubMed</a>                                            	    											                                                                                                <ul>                                                    <li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=citalopram[All Fields]" title="Link opens new window for All Citations" target="pubmed">All Citations</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=citalopram/AE" title="Link opens new window for Adverse Effects" target="pubmed">Adverse Effects</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=citalopram/TU"  title="Link opens new window for Therapeutic Use" target="pubmed">Therapeutic Use</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=citalopram/PD" title="Link opens new window for Pharmacology" target="pubmed">Pharmacology</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=citalopram[All Fields] AND Clinical Trial[ptyp]" title="Link opens new window for Clinical Trials" target="pubmed">Clinical Trials</a>                                                    </li>                                                </ul>                                            </li>                                            <li>                                                <a href="http://www.drugbank.ca/search?utf8=%E2%9C%93&query=APRD00147&search_type=drugs&button=" target="_blank">Biochemical Data Summary</a>                                            </li>                                                                            </ul>                                </div>                                <div class="mod blue-list">                                    <h2><a href="#">More Info For This Drug</a></h2>                                    <ul>                                    	                                        <li><a href="#modal-label-archives" class="modal-open">View Label Archives</a></li>                                        <li><a href="#modal-rx-norm" class="modal-open">RxNorm</a></li>                                                                                <li><a href="#modal-label-rss" class="modal-open">Get Label RSS Feed</a></li>                                    </ul>                                </div>                                                            </div>                        </article>                    </section>                </div>                               <div class="content-wide">                        <article>                            <ul class="drug-information">                            	                                                                <li>                                <strong><a class="tip" rel="tooltip" title="NDC (National Drug Code) - Each drug product is assigned this unique number which can be found on the drug's outer packaging." href="#">NDC Code(s):</a></strong> <span id="item-code-s">                                                                                                	                                    0456-4010-01,                                                                                                                                        	                                    0456-4020-01,                                                                                                                                        	                                    0456-4020-11,                                                                                                                                        	                                    0456-4020-63,                                                                        	<a class="view-more show-js" href="#">view more</a><div class="more-codes"><span>                                                                                                                                        	                                    0456-4040-01,                                                                                                                                        	                                    0456-4040-11,                                                                                                                                        	                                    0456-4040-63                                                                                                                                                                        	</span>                                    </div>                                                                								</li>                                <li>                                                                                                                                                                <li><strong>Packager: </strong>Forest Laboratories, Inc.</li>                                						    	    																																			    																	    	    	                             		       	                                                                                                                                                           </ul>                                                        <ul class="drug-information">                            	                                <li><strong>Category:</strong>                                 	                                    	<span id="category" class="orangetext">                                                                            	HUMAN PRESCRIPTION DRUG LABEL</span></li>                                                                    <li><strong>DEA Schedule:</strong> <span id="dea-schedule">                                                                        	None                                                                        </span></li>                                                                    <li><strong>Marketing Status:</strong> <span id="marketing-status">New Drug Application</span></li>								                            </ul>							                                    <div id="drug-information" class="toggle">                                                                                    <h2><a id="druglabel"></a>Drug Label Information</h2>                                                 <p class="date">Updated                                                  	                                                    	07/14                                                                                                     </p>                                                   <p class="orangetext">If you are a consumer or patient please visit <a href="dailymed/drugInfo.cfm?setid=4259d9b1-de34-43a4-85a8-41dd214e9177&audience=consumer">this version.</a></p>                                                                                                   <ul class="tools">                                                    <li class="download">Download DRUG LABEL INFO: <a class="pdf" href="dailymed/getFile.cfm?setid=4259d9b1-de34-43a4-85a8-41dd214e9177&amp;type=pdf&amp;name=4259d9b1-de34-43a4-85a8-41dd214e9177" target="_blank">PDF</a>                                                    	<a class="xml" href="dailymed/getFile.cfm?setid=4259d9b1-de34-43a4-85a8-41dd214e9177&amp;type=zip&amp;name=CELEXA">XML</a>                                                    </li>                                                                                                                                                            <li class="medguide">Medication Guide:                                                         <a href="dailymed/medguide.cfm?setid=4259d9b1-de34-43a4-85a8-41dd214e9177" target="_blank">HTML</a>                                                                                                            </li>                                                                                                        <li class="print">                                                        <a href="dailymed/fda/fdaDrugXsl.cfm?setid=4259d9b1-de34-43a4-85a8-41dd214e9177&amp;type=display" target="_blank">Print Drug Label Info</a>                                                    </li>                                                                                                    </ul>                                                                                                  <div class="drug-label-sections">                                                   <div class="control-nav show-js">                                            <a class="open-all" href="#">View All Sections</a><a class="close-all" href="#">Close All Sections</a>                                        </div>                                                                        <ul>                                                                                        	                                                <li id="boxedwarning"><a href="#">BOXED WARNING</a><a class=" tip" rel="tooltip" href="#" title="A boxed warning is the strongest warning that the FDA requires, and signifies that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects.">(What is this?)</a> <div class="Warning toggle-content open">   <a name="s2"></a>  <a name="section-2"></a>   <p></p>   <h1>Suicidality and Antidepressant Drugs</h1>   <p class="First"> <span class="Bold">Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of Celexa or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Celexa is not approved for use in pediatric patients. (See <a href="#s16">WARNINGS: Clinical Worsening and Suicide Risk</a>, <a href="#s29">PRECAUTIONS: Information for Patients</a>, and <a href="#s61">PRECAUTIONS: Pediatric Use</a>.)</span> </p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">SPL UNCLASSIFIED SECTION</a> <div class="Section toggle-content closed" data-sectioncode="42229-5">   <a name="s1"></a>  <a name="section-1"></a>   <p></p>   <p class="First"> <span class="Bold">Rx Only</span> </p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">DESCRIPTION</a> <div class="Section toggle-content closed" data-sectioncode="34089-3">   <a name="s3"></a>  <a name="section-2"></a>   <p></p>    <p class="First">Celexa&reg; (citalopram HBr) is an orally administered selective serotonin reuptake inhibitor (SSRI) with a chemical structure unrelated to that of other SSRIs or of tricyclic, tetracyclic, or other available antidepressant agents. Citalopram HBr is a racemic bicyclic phthalane derivative designated (&plusmn;)-1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile, HBr with the following structural formula:</p>   <div class="Figure">    <a name="f01"></a>   <img src="image.cfm?setid=4259d9b1-de34-43a4-85a8-41dd214e9177&name=cel00%2D0019%2D01%2Ejpg" alt="Structural Formula" />  </div>   <p>The molecular formula is C<span class="Sub">20</span>H<span class="Sub">22</span>BrFN<span class="Sub">2</span>O and its molecular weight is 405.35.</p>   <p>Citalopram HBr occurs as a fine, white to off-white powder. Citalopram HBr is sparingly soluble in water and soluble in ethanol.</p>   <p>Celexa (citalopram hydrobromide) is available only in tablet dosage form.</p>   <p>Celexa 10 mg are film-coated, oval tablets containing citalopram HBr in strengths equivalent to 10 mg citalopram base. Celexa 20 mg and 40 mg are film-coated, oval, scored tablets containing citalopram HBr in strengths equivalent to 20 mg or 40 mg citalopram base. The tablets also contain the following inactive ingredients: copolyvidone, corn starch, crosscarmellose sodium, glycerin, lactose monohydrate, magnesium stearate, hypromellose, microcrystalline cellulose, polyethylene glycol, and titanium dioxide. Iron oxides are used as coloring agents in the beige (10 mg) and pink (20 mg) tablets.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">CLINICAL PHARMACOLOGY</a> <div class="Section toggle-content closed" data-sectioncode="34090-1">   <a name="s4"></a>  <a name="section-3"></a>   <p></p>    <div class="Section" data-sectioncode="43681-6">    <a name="s5"></a>   <a name="section-3.1"></a>    <p></p>    <h2>Pharmacodynamics</h2>    <p class="First">The mechanism of action of citalopram HBr as an antidepressant is presumed to be linked to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT). <span class="Italics">In vitro</span> and <span class="Italics">in vivo</span> studies in animals suggest that citalopram is a highly selective serotonin reuptake inhibitor (SSRI) with minimal effects on norepinephrine (NE) and dopamine (DA) neuronal reuptake. Tolerance to the inhibition of 5-HT uptake is not induced by long-term (14-day) treatment of rats with citalopram. Citalopram is a racemic mixture (50/50), and the inhibition of 5-HT reuptake by citalopram is primarily due to the (S)-enantiomer.</p>    <p>Citalopram has no or very low affinity for 5-HT<span class="Sub">1A</span>, 5-HT<span class="Sub">2A</span>, dopamine D<span class="Sub">1</span> and D<span class="Sub">2</span>, α<span class="Sub">1</span>-, α<span class="Sub">2</span>-, and β-adrenergic, histamine H<span class="Sub">1</span>, gamma aminobutyric acid (GABA), muscarinic cholinergic, and benzodiazepine receptors. Antagonism of muscarinic, histaminergic, and adrenergic receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects of other psychotropic drugs.</p>   </div>   <div class="Section" data-sectioncode="43682-4">    <a name="s6"></a>   <a name="section-3.2"></a>    <p></p>    <h2>Pharmacokinetics</h2>    <p class="First">The single- and multiple-dose pharmacokinetics of citalopram are linear and dose-proportional in a dose range of 10-60 mg/day. Biotransformation of citalopram is mainly hepatic, with a mean terminal half-life of about 35 hours. With once daily dosing, steady state plasma concentrations are achieved within approximately one week. At steady state, the extent of accumulation of citalopram in plasma, based on the half-life, is expected to be 2.5 times the plasma concentrations observed after a single dose.</p>    <div class="Section" data-sectioncode="42229-5">     <a name="s7"></a>    <a name="section-3.2.1"></a>     <p></p>     <h3>Absorption and Distribution</h3>     <p class="First">Following a single oral dose (40 mg tablet) of citalopram, peak blood levels occur at about 4 hours. The absolute bioavailability of citalopram was about 80% relative to an intravenous dose, and absorption is not affected by food. The volume of distribution of citalopram is about 12 L/kg and the binding of citalopram (CT), demethylcitalopram (DCT) and didemethylcitalopram (DDCT) to human plasma proteins is about 80%.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s8"></a>    <a name="section-3.2.2"></a>     <p></p>     <h3>Metabolism and Elimination</h3>     <p class="First">Following intravenous administrations of citalopram, the fraction of drug recovered in the urine as citalopram and DCT was about 10% and 5%, respectively. The systemic clearance of citalopram was 330 mL/min, with approximately 20% of that due to renal clearance.</p>     <p>Citalopram is metabolized to demethylcitalopram (DCT), didemethylcitalopram (DDCT), citalopram-N-oxide, and a deaminated propionic acid derivative. In humans, unchanged citalopram is the predominant compound in plasma. At steady state, the concentrations of citalopram's metabolites, DCT and DDCT, in plasma are approximately one-half and one-tenth, respectively, that of the parent drug. <span class="Italics">In vitro</span> studies show that citalopram is at least 8 times more potent than its metabolites in the inhibition of serotonin reuptake, suggesting that the metabolites evaluated do not likely contribute significantly to the antidepressant actions of citalopram.</p>     <p> <span class="Italics">In vitro</span> studies using human liver microsomes indicated that CYP3A4 and CYP2C19 are the primary isozymes involved in the N-demethylation of citalopram.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s9"></a>    <a name="section-3.2.3"></a>     <p></p>     <h3>Population Subgroups</h3>     <p class="First">Age - Citalopram pharmacokinetics in subjects ≥ 60 years of age were compared to younger subjects in two normal volunteer studies. In a single-dose study, citalopram AUC and half-life were increased in the subjects ≥ 60 years old by 30% and 50%, respectively, whereas in a multiple-dose study they were increased by 23% and 30%, respectively. 20 mg/day is the maximum recommended dose for patients who are greater than 60 years of age (see <span class="Bold"><a href="#s15">WARNINGS</a></span> and <span class="Bold"><a href="#s95">DOSAGE AND ADMINISTRATION</a></span>), due to the risk of QT prolongation.</p>     <p>Gender - In three pharmacokinetic studies (total N=32), citalopram AUC in women was one and a half to two times that in men. This difference was not observed in five other pharmacokinetic studies (total N=114). In clinical studies, no differences in steady state serum citalopram levels were seen between men (N=237) and women (N=388). There were no gender differences in the pharmacokinetics of DCT and DDCT. No adjustment of dosage on the basis of gender is recommended.</p>     <p>Reduced hepatic function - Citalopram oral clearance was reduced by 37% and half-life was doubled in patients with reduced hepatic function compared to normal subjects. 20 mg/day is the maximum recommended dose for hepatically impaired patients (see <span class="Bold"><a href="#s15">WARNINGS</a></span> and <span class="Bold"><a href="#s95">DOSAGE AND ADMINISTRATION</a></span>), due to the risk of QT prolongation.</p>     <p> CYP2C19 poor metabolizers -– In CYP2C19 poor metabolizers, citalopram steady state Cmax and AUC was increased by 68% and 107%, respectively. Celexa 20 mg/day is the maximum recommended dose in CYP2C19 poor metabolizers due to the risk of QT prolongation (see <span class="Bold"><a href="#s15">WARNINGS</a></span> and <span class="Bold"><a href="#s95">DOSAGE AND ADMINISTRATION</a></span>). </p>     <p> CYP2D6 poor metabolizers - Citalopram steady state levels were not significantly different in poor metabolizers and extensive metabolizers of CYP2D6. </p>     <p>Reduced renal function - In patients with mild to moderate renal function impairment, oral clearance of citalopram was reduced by 17% compared to normal subjects. No adjustment of dosage for such patients is recommended. No information is available about the pharmacokinetics of citalopram in patients with severely reduced renal function (creatinine clearance &lt; 20 mL/min).</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s10"></a>    <a name="section-3.2.4"></a>     <p></p>     <h3>Drug-Drug Interactions</h3>     <p class="First"> <span class="Italics">In vitro</span> enzyme inhibition data did not reveal an inhibitory effect of citalopram on CYP3A4, -2C9, or -2E1, but did suggest that it is a weak inhibitor of CYP1A2, -2D6, and -2C19. Citalopram would be expected to have little inhibitory effect on <span class="Italics">in vivo</span> metabolism mediated by these enzymes. However, <span class="Italics">in vivo</span> data to address this question are limited.</p>     <p>CYP3A4 and CYP 2C19 inhibitors: Since CYP3A4 and CYP 2C19 are the primary enzymes involved in the metabolism of citalopram, it is expected that potent inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, and macrolide antibiotics) and potent inhibitors of CYP2C19 (e.g., omeprazole) might decrease the clearance of citalopram. However, coadministration of citalopram and the potent CYP3A4 inhibitor ketoconazole did not significantly affect the pharmacokinetics of citalopram. Celexa 20 mg/day is the maximum recommended dose in patients taking concomitant cimetidine or another CYP2C19 inhibitor, because of the risk of QT prolongation (see <span class="Bold"><a href="#s15">WARNINGS</a></span> and <span class="Bold"><a href="#s95">DOSAGE AND ADMINISTRATION</a></span>).</p>     <p> CYP2D6 Inhibitors: Coadministration of a drug that inhibits CYP2D6 with Celexa is unlikely to have clinically significant effects on citalopram metabolism, based on the study results in CYP2D6 poor metabolizers. </p>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s11"></a>   <a name="section-3.3"></a>    <p></p>    <h2>Clinical Efficacy Trials</h2>    <p class="First">The efficacy of Celexa as a treatment for depression was established in two placebo-controlled studies (of 4 to 6 weeks in duration) in adult outpatients (ages 18-66) meeting DSM-III or DSM-III-R criteria for major depression. Study 1, a 6-week trial in which patients received fixed Celexa doses of 10, 20, 40, and 60 mg/day, showed that Celexa at doses of 40 and 60 mg/day was effective as measured by the Hamilton Depression Rating Scale (HAMD) total score, the HAMD depressed mood item (Item 1), the Montgomery Asberg Depression Rating Scale, and the Clinical Global Impression (CGI) Severity scale. This study showed no clear effect of the 10 and 20 mg/day doses, and the 60 mg/day dose was not more effective than the 40 mg/day dose. In study 2, a 4-week, placebo-controlled trial in depressed patients, of whom 85% met criteria for melancholia, the initial dose was 20 mg/day, followed by titration to the maximum tolerated dose or a maximum dose of 80 mg/day. Patients treated with Celexa showed significantly greater improvement than placebo patients on the HAMD total score, HAMD item 1, and the CGI Severity score. In three additional placebo-controlled depression trials, the difference in response to treatment between patients receiving Celexa and patients receiving placebo was not statistically significant, possibly due to high spontaneous response rate, smaller sample size, or, in the case of one study, too low a dose.</p>    <p>In two long-term studies, depressed patients who had responded to Celexa during an initial 6 or 8 weeks of acute treatment (fixed doses of 20 or 40 mg/day in one study and flexible doses of 20-60 mg/day in the second study) were randomized to continuation of Celexa or to placebo. In both studies, patients receiving continued Celexa treatment experienced significantly lower relapse rates over the subsequent 6 months compared to those receiving placebo. In the fixed-dose study, the decreased rate of depression relapse was similar in patients receiving 20 or 40 mg/day of Celexa.</p>    <p>Analyses of the relationship between treatment outcome and age, gender, and race did not suggest any differential responsiveness on the basis of these patient characteristics.</p>    <div class="Section" data-sectioncode="34092-7">     <a name="s12"></a>    <a name="section-3.3.1"></a>     <p></p>     <h3>Comparison of Clinical Trial Results</h3>     <p class="First">Highly variable results have been seen in the clinical development of all antidepressant drugs. Furthermore, in those circumstances when the drugs have not been studied in the same controlled clinical trial(s), comparisons among the results of studies evaluating the effectiveness of different antidepressant drug products are inherently unreliable. Because conditions of testing (e.g., patient samples, investigators, doses of the treatments administered and compared, outcome measures, etc.) vary among trials, it is virtually impossible to distinguish a difference in drug effect from a difference due to one of the confounding factors just enumerated.</p>    </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">INDICATIONS AND USAGE</a> <div class="Section toggle-content closed" data-sectioncode="34067-9">   <a name="s13"></a>  <a name="section-4"></a>   <p></p>    <p class="First">Celexa (citalopram HBr) is indicated for the treatment of depression.</p>   <p>The efficacy of Celexa in the treatment of depression was established in 4-6 week, controlled trials of outpatients whose diagnosis corresponded most closely to the DSM-III and DSM-III-R category of major depressive disorder (see <span class="Bold"><a href="#s4">CLINICAL PHARMACOLOGY</a></span>).</p>   <p>A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation.</p>   <p>The antidepressant action of Celexa in hospitalized depressed patients has not been adequately studied.</p>   <p>The efficacy of Celexa in maintaining an antidepressant response for up to 24 weeks following 6 to 8 weeks of acute treatment was demonstrated in two placebo-controlled trials (see <span class="Bold"><a href="#s4">CLINICAL PHARMACOLOGY</a></span>). Nevertheless, the physician who elects to use Celexa for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">CONTRAINDICATIONS</a> <div class="Section toggle-content closed" data-sectioncode="34070-3">   <a name="s14"></a>  <a name="section-5"></a>   <p></p>    <p class="First">The use of MAOIs intended to treat psychiatric disorders with Celexa or within 14 days of stopping treatment with Celexa is contraindicated because of an increased risk of serotonin syndrome. The use of Celexa within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated (see <span class="Bold"><a href="#s15">WARNINGS</a> and <a href="#s100">DOSAGE and ADMINISTRATION</a></span>).</p>   <p>Starting Celexa in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see <span class="Bold"><a href="#s15">WARNINGS</a> and <a href="#s100">DOSAGE AND ADMINISTRATION</a></span>).</p>   <p>Concomitant use in patients taking pimozide is contraindicated (see <span class="Bold"><a href="#s21">PRECAUTIONS</a></span>).</p>   <p>Celexa is contraindicated in patients with a hypersensitivity to citalopram or any of the inactive ingredients in Celexa.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">WARNINGS</a> <div class="Section toggle-content closed" data-sectioncode="34071-1">   <a name="s15"></a>  <a name="section-6"></a>   <p></p>    <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">WARNINGS-Clinical Worsening and Suicide Risk</a> <div class="Section toggle-content closed" data-sectioncode="42229-5">   <a name="s16"></a>  <a name="section-7"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="s17"></a>   <a name="section-7.1"></a>    <p></p>    <h2>Clinical Worsening and Suicide Risk</h2>    <p class="First">Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide. There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment.</p>    <p>Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18-24) with major depressive disorder (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older. </p>    <p>The pooled analyses of placebo-controlled trials in children and adolescents with MDD, obsessive compulsive disorder (OCD), or other psychiatric disorders included a total of 24 short-term trials of 9 antidepressant drugs in over 4400 patients. The pooled analyses of placebo-controlled trials in adults with MDD or other psychiatric disorders included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences (drug vs. placebo), however, were relatively stable within age strata and across indications. These risk differences (drug-placebo difference in the number of cases of suicidality per 1000 patients treated) are provided in <span class="Bold"><a href="#t1">Table 1</a>.</span> </p>    <a name="t1"></a>    <div class="scrollingtable">    <table width="100%">      <caption>       <span>TABLE 1 </span>      </caption>      <colgroup>      <col align="left" width="46.800%" />       <col align="left" width="53.200%" />      </colgroup>     <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Age Range</span></td>       <td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Drug-Placebo Difference in Number of Cases of Suicidality per 1000 Patients Treated</span></td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center" valign="top"></td>       <td class="Botrule Rrule" align="center" valign="top">Increases<br />Compared to Placebo</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center" valign="top">&lt;18</td>       <td class="Botrule Rrule" align="center" valign="top">14 additional cases</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center" valign="top">18-24</td>       <td class="Botrule Rrule" align="center" valign="top">5 additional cases</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center" valign="top"></td>       <td class="Botrule Rrule" align="center" valign="top">Decreases<br />Compared to Placebo</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center" valign="top">25-64</td>       <td class="Botrule Rrule" align="center" valign="top">1 fewer case</td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Rrule" align="center" valign="top">≥65</td>       <td class="Botrule Rrule" align="center" valign="top">6 fewer cases</td>       </tr>      </tbody>     </table>   </div>    <p>No suicides occurred in any of the pediatric trials. There were suicides in the adult trials, but the number was not sufficient to reach any conclusion about drug effect on suicide.</p>    <p>It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with depression that the use of antidepressants can delay the recurrence of depression.</p>    <p> <span class="Bold">All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.</span> </p>    <p>The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality.</p>    <p>Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms. </p>    <p>If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms (see <a href="#s21">PRECAUTIONS</a> and <a href="#s100">DOSAGE AND ADMINISTRATION—Discontinuation of Treatment with Celexa</a>, for a description of the risks of discontinuation of Celexa).</p>    <p> <span class="Bold">Families and caregivers of patients being treated with antidepressants for major depressive disorder or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to health care providers. Such monitoring should include daily observation by families and caregivers.</span> Prescriptions for Celexa should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="e18"></a>   <a name="section-7.2"></a>    <p></p>    <h2> QT-Prolongation and Torsade de Pointes </h2>    <p class="First">Citalopram causes dose-dependent QTc prolongation, an ECG abnormality that has been associated with Torsade de Pointes (TdP), ventricular tachycardia, and sudden death, all of which have been observed in postmarketing reports for citalopram. </p>    <p>Individually corrected QTc (QTcNi) interval was evaluated in a randomized, placebo and active (moxifloxacin 400 mg) controlled cross-over, escalating multiple-dose study in 119 healthy subjects. The maximum mean (upper bound of the 95% one-sided confidence interval) difference from placebo were 8.5 (10.8) and 18.5 (21.0) msec for 20 mg and 60 mg citalopram, respectively. Based on the established exposure-response relationship, the predicted QTcNi change from placebo (upper bound of the 95% one-sided confidence interval) under the C<span class="Sub">max</span> for the dose of 40 mg is 12.6 (14.3) msec.</p>    <p> Because of the risk of QTc prolongation at higher citalopram doses, it is recommended that citalopram should not be given at doses above 40 mg/day. </p>    <p> It is recommended that citalopram should not be used in patients with congenital long QT syndrome, bradycardia, hypokalemia or hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure. Citalopram should also not be used in patients who are taking other drugs that prolong the QTc interval. Such drugs include Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval (e.g., pentamidine, levomethadyl acetate, methadone). </p>    <p> The citalopram dose should be limited in certain populations. The maximum dose should be limited to 20 mg/day in patients who are CYP2C19 poor metabolizers or those patients who may be taking concomitant cimetidine or another CYP2C19 inhibitor, since higher citalopram exposures would be expected. The maximum dose should also be limited to 20 mg/day in patients with hepatic impairment and in patients who are greater than 60 years of age because of expected higher exposures. </p>    <p> Electrolyte and/or ECG monitoring is recommended in certain circumstances. Patients being considered for citalopram treatment who are at risk for significant electrolyte disturbances should have baseline serum potassium and magnesium measurements with periodic monitoring. Hypokalemia (and/or hypomagnesemia) may increase the risk of QTc prolongation and arrhythmia, and should be corrected prior to initiation of treatment and periodically monitored. ECG monitoring is recommended in patients for whom citalopram use is not recommended (see above), but, nevertheless, considered essential. These include those patients with the cardiac conditions noted above, and those taking other drugs that may prolong the QTc interval. </p>    <p> Citalopram should be discontinued in patients who are found to have persistent QTc measurements &gt;500 ms. If patients taking citalopram experience symptoms that could indicate the occurrence of cardiac arrhythmias, e.g., dizziness, palpitations, or syncope, the prescriber should initiate further evaluation, including cardiac monitoring.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s18"></a>   <a name="section-7.3"></a>    <p></p>    <p class="First"> <span class="Bold">Screening Patients for Bipolar Disorder:</span> A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. It should be noted that Celexa is not approved for use in treating bipolar depression.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s20"></a>   <a name="section-7.4"></a>    <p></p>    <h2>Serotonin Syndrome</h2>    <p class="First">The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs, including Celexa, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, trytophan, buspirone, and St. John's Wort) and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue). </p>    <p>Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Patients should be monitored for the emergence of serotonin syndrome.</p>    <p>The concomitant use of Celexa with MAOIs intended to treat psychiatric disorders is contraindicated. Celexa should also not be started in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue. All reports with methylene blue that provided information on the route of administration involved intravenous administration in the dose range of 1 mg/kg to 8 mg/kg. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection) or at lower doses. There may be circumstances when it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking Celexa. Celexa should be discontinued before initiating treatment with the MAOI (see <span class="Bold"><a href="#s14">CONTRAINDICATIONS</a> and <a href="#s100">DOSAGE AND ADMINISTRATION</a></span>).</p>    <p>If concomitant use of Celexa with other serotonergic drugs including, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, trytophan and St. John's Wort is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome particularly during treatment initiation and dose increases.</p>    <p>Treatment with Celexa and any concomitant serotonergic agents should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="e20"></a>   <a name="section-7.5"></a>    <p></p>    <h2>Angle Closure Glaucoma</h2>    <p class="First">The pupillary dilation that occurs following use of many antidepressant drugs including Celexa may trigger an angle closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy. </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRECAUTIONS</a> <div class="Section toggle-content closed" data-sectioncode="42232-9">   <a name="s21"></a>  <a name="section-8"></a>   <p></p>    <div class="Section" data-sectioncode="34072-9">    <a name="e21"></a>   <a name="section-8.1"></a>    <p></p>    <h2>General</h2>    <div class="Section" data-sectioncode="42229-5">     <a name="s22"></a>    <a name="section-8.1.1"></a>     <p></p>     <h3>Discontinuation of Treatment with Celexa</h3>     <p class="First">During marketing of Celexa and other SSRIs and SNRIs (serotonin and norepinephrine reuptake inhibitors), there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesias such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, and hypomania. While these events are generally self-limiting, there have been reports of serious discontinuation symptoms.</p>     <p>Patients should be monitored for these symptoms when discontinuing treatment with Celexa. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate (see <span class="Bold"><a href="#s95">DOSAGE AND ADMINISTRATION</a></span>).</p>     <div class="Section" data-sectioncode="42229-5">      <a name="s23"></a>     <a name="section-8.1.1.1"></a>      <p></p>      <h4>Abnormal Bleeding</h4>      <p class="First">SSRIs and SNRIs, including Celexa, may increase the risk of bleeding events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, warfarin, and other anticoagulants may add to the risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding. Bleeding events related to SSRIs and SNRIs use have ranged from ecchymoses, hematomas, epistaxis, and petechiae to life-threatening hemorrhages.</p>      <p>Patients should be cautioned about the risk of bleeding associated with the concomitant use of Celexa and NSAIDs, aspirin, or other drugs that affect coagulation.</p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="s24"></a>     <a name="section-8.1.1.2"></a>      <p></p>      <h4>Hyponatremia</h4>      <p class="First">Hyponatremia may occur as a result of treatment with SSRIs and SNRIs, including Celexa. In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH), and was reversible when Celexa was discontinued. Cases with serum sodium lower than 110 mmol/L have been reported. Elderly patients may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk (see <a href="#s62">Geriatric Use</a>). Discontinuation of Celexa should be considered in patients with symptomatic hyponatremia and appropriate medical intervention should be instituted.</p>      <p>Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which may lead to falls. Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death.</p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="s25"></a>     <a name="section-8.1.1.3"></a>      <p></p>      <h4>Activation of Mania/Hypomania</h4>      <p class="First">In placebo-controlled trials of Celexa, some of which included patients with bipolar disorder, activation of mania/hypomania was reported in 0.2% of 1063 patients treated with Celexa and in none of the 446 patients treated with placebo. Activation of mania/hypomania has also been reported in a small proportion of patients with major affective disorders treated with other marketed antidepressants. As with all antidepressants, Celexa should be used cautiously in patients with a history of mania.</p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="s26"></a>     <a name="section-8.1.1.4"></a>      <p></p>      <h4>Seizures</h4>      <p class="First">Although anticonvulsant effects of citalopram have been observed in animal studies, Celexa has not been systematically evaluated in patients with a seizure disorder. These patients were excluded from clinical studies during the product's premarketing testing. In clinical trials of Celexa, seizures occurred in 0.3% of patients treated with Celexa (a rate of one patient per 98 years of exposure) and 0.5% of patients treated with placebo (a rate of one patient per 50 years of exposure). Like other antidepressants, Celexa should be introduced with care in patients with a history of seizure disorder.</p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="s27"></a>     <a name="section-8.1.1.5"></a>      <p></p>      <h4>Interference with Cognitive and Motor Performance</h4>      <p class="First">In studies in normal volunteers, Celexa in doses of 40 mg/day did not produce impairment of intellectual function or psychomotor performance. Because any psychoactive drug may impair judgment, thinking, or motor skills, however, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that Celexa therapy does not affect their ability to engage in such activities.</p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="s28"></a>     <a name="section-8.1.1.6"></a>      <p></p>      <h4>Use in Patients with Concomitant Illness</h4>      <p class="First">Clinical experience with Celexa in patients with certain concomitant systemic illnesses is limited. Due to the risk of QT prolongation, citalopram use should be avoided in patients with certain cardiac conditions, and ECG monitoring is advised if Celexa must be used in such patients. Electrolytes should be monitored in treating patients with diseases or conditions that cause hypokalemia or hypomagnesemia. (see <span class="Bold"><a href="#s15">WARNINGS</a></span>). </p>      <p>In subjects with hepatic impairment, citalopram clearance was decreased and plasma concentrations were increased. The use of Celexa in hepatically impaired patients should be approached with caution and a lower maximum dosage is recommended (see <span class="Bold"><a href="#s95">DOSAGE AND ADMINISTRATION</a></span>).</p>      <p>Because citalopram is extensively metabolized, excretion of unchanged drug in urine is a minor route of elimination. Until adequate numbers of patients with severe renal impairment have been evaluated during chronic treatment with Celexa, however, it should be used with caution in such patients (see <span class="Bold"><a href="#s95">DOSAGE AND ADMINISTRATION</a></span>).</p>     </div>    </div>   </div>   <div class="Section" data-sectioncode="34076-0">    <a name="s29"></a>   <a name="section-8.2"></a>    <p></p>    <h2>Information for Patients</h2>    <p class="First">Physicians are advised to discuss the following issues with patients for whom they prescribe Celexa.</p>    <p>Patients should be cautioned about the risk of serotonin syndrome with the concomitant use of <span class="Bold">Celexa</span> and triptans, tramadol or other serotonergic agents.</p>    <p>Patients should be advised that taking Celexa can cause mild pupillary dilation, which in susceptible individuals, can lead to an episode of angle closure glaucoma. Pre-existing glaucoma is almost always open-angle glaucoma because angle closure glaucoma, when diagnosed, can be treated definitively with iridectomy. Open-angle glaucoma is not a risk factor for angle closure glaucoma. Patients may wish to be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible. </p>    <p>Although in controlled studies Celexa has not been shown to impair psychomotor performance, any psychoactive drug may impair judgment, thinking, or motor skills, so patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that Celexa therapy does not affect their ability to engage in such activities.</p>    <p>Patients should be told that, although Celexa has not been shown in experiments with normal subjects to increase the mental and motor skill impairments caused by alcohol, the concomitant use of Celexa and alcohol in depressed patients is not advised.</p>    <p>Patients should be advised to inform their physician if they are taking, or plan to take, any prescription or over-the-counter drugs, as there is a potential for interactions.</p>    <p>Patients should be cautioned about the concomitant use of Celexa and NSAIDs, aspirin, warfarin, or other drugs that affect coagulation since combined use of psychotropic drugs that interfere with serotonin reuptake and these agents has been associated with an increased risk of bleeding.</p>    <p>Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during therapy.</p>    <p>Patients should be advised to notify their physician if they are breastfeeding an infant.</p>    <p>While patients may notice improvement with Celexa therapy in 1 to 4 weeks, they should be advised to continue therapy as directed.</p>    <p>Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with Celexa and should counsel them in its appropriate use. A patient Medication Guide about “Antidepressant Medicines, Depression and other Serious Mental Illness, and Suicidal Thoughts or Actions” is available for Celexa. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. The complete text of the Medication Guide is reprinted at the end of this document.</p>    <p>Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking Celexa.</p>    <div class="Section" data-sectioncode="42229-5">     <a name="s30"></a>    <a name="section-8.2.1"></a>     <p></p>     <p class="First"> <span class="Bold">Clinical Worsening and Suicide Risk:</span> Patients, their families, and their caregivers should be encouraged to be alert to the emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, mania, other unusual changes in behavior, worsening of depression, and suicidal ideation, especially early during antidepressant treatment and when the dose is adjusted up or down. Families and caregivers of patients should be advised to look for the emergence of such symptoms on a day-to-day basis, since changes may be abrupt. Such symptoms should be reported to the patient's prescriber or health professional, especially if they are severe, abrupt in onset, or were not part of the patient's presenting symptoms. Symptoms such as these may be associated with an increased risk for suicidal thinking and behavior and indicate a need for very close monitoring and possibly changes in the medication.</p>    </div>   </div>   <div class="Section" data-sectioncode="34075-2">    <a name="s31"></a>   <a name="section-8.3"></a>    <p></p>    <h2>Laboratory Tests</h2>    <p class="First">There are no specific laboratory tests recommended.</p>   </div>   <div class="Section" data-sectioncode="34073-7">    <a name="s32"></a>   <a name="section-8.4"></a>    <p></p>    <h2>Drug Interactions</h2>    <div class="Section" data-sectioncode="42229-5">     <a name="s33"></a>    <a name="section-8.4.1"></a>     <p></p>     <p class="First"> <span class="Bold">Serotonergic Drugs</span>: See <span class="Bold"><a href="#s14">CONTRAINDICATIONS</a>, <a href="#s15">WARNINGS</a>, and <a href="#s100">DOSAGE AND ADMINISTRATION</a>.</span> </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s34"></a>    <a name="section-8.4.2"></a>     <p></p>     <p class="First"> <span class="Bold">Triptans</span>: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan. If concomitant treatment of Celexa with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see <span class="Bold"><a href="#s20">WARNINGS - Serotonin Syndrome</a></span>).</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s35"></a>    <a name="section-8.4.3"></a>     <p></p>     <p class="First">CNS Drugs - Given the primary CNS effects of citalopram, caution should be used when it is taken in combination with other centrally acting drugs.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s36"></a>    <a name="section-8.4.4"></a>     <p></p>     <p class="First">Alcohol - Although citalopram did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by depressed patients taking Celexa is not recommended.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s37"></a>    <a name="section-8.4.5"></a>     <p></p>     <p class="First">Monoamine Oxidase Inhibitors (MAOIs) - See <span class="Bold"><a href="#s14">CONTRAINDICATIONS</a></span>, <span class="Bold"><a href="#s15">WARNINGS</a> and <a href="#s100">DOSAGE AND ADMINISTRATION</a></span>.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s38"></a>    <a name="section-8.4.6"></a>     <p></p>     <p class="First">Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, Warfarin, etc.) - Serotonin release by platelets plays an important role in hemostasis. Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin may potentiate the risk of bleeding. Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs and SNRIs are coadministered with warfarin. Patients receiving warfarin therapy should be carefully monitored when Celexa is initiated or discontinued.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s39"></a>    <a name="section-8.4.7"></a>     <p></p>     <p class="First">Cimetidine - In subjects who had received 21 days of 40 mg/day Celexa, combined administration of 400 mg twice a day cimetidine for 8 days resulted in an increase in citalopram AUC and C<span class="Sub">max</span> of 43% and 39%, respectively. </p>     <p> Celexa 20 mg/day is the maximum recommended dose for patients taking concomitant cimetidine because of the risk of QT prolongation (see <span class="Bold"><a href="#s15">WARNINGS</a></span> and <span class="Bold"><a href="#s95">DOSAGE AND ADMINISTRATION</a></span>). </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s40"></a>    <a name="section-8.4.8"></a>     <p></p>     <p class="First">Digoxin - In subjects who had received 21 days of 40 mg/day Celexa, combined administration of Celexa and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s41"></a>    <a name="section-8.4.9"></a>     <p></p>     <p class="First">Lithium - Coadministration of Celexa (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium. Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice. Because lithium may enhance the serotonergic effects of citalopram, caution should be exercised when Celexa and lithium are coadministered.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s42"></a>    <a name="section-8.4.10"></a>     <p></p>     <p class="First">Pimozide - In a controlled study, a single dose of pimozide 2 mg co-administered with citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone. Citalopram did not alter the mean AUC or C<span class="Sub">max</span> of pimozide. The mechanism of this pharmacodynamic interaction is not known.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s43"></a>    <a name="section-8.4.11"></a>     <p></p>     <p class="First">Theophylline - Combined administration of Celexa (40 mg/day for 21 days) and the CYP1A2 substrate theophylline (single dose of 300 mg) did not affect the pharmacokinetics of theophylline. The effect of theophylline on the pharmacokinetics of citalopram was not evaluated.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s44"></a>    <a name="section-8.4.12"></a>     <p></p>     <p class="First">Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a SSRI and sumatriptan. If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram) is clinically warranted, appropriate observation of the patient is advised.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s45"></a>    <a name="section-8.4.13"></a>     <p></p>     <p class="First">Warfarin - Administration of 40 mg/day Celexa for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate. Prothrombin time was increased by 5%, the clinical significance of which is unknown.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s46"></a>    <a name="section-8.4.14"></a>     <p></p>     <p class="First">Carbamazepine - Combined administration of Celexa (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate. Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of citalopram should be considered if the two drugs are coadministered.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s47"></a>    <a name="section-8.4.15"></a>     <p></p>     <p class="First">Triazolam - Combined administration of Celexa (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or triazolam.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s48"></a>    <a name="section-8.4.16"></a>     <p></p>     <p class="First">Ketoconazole - Combined administration of Celexa (40 mg) and ketoconazole (200 mg) decreased the C<span class="Sub">max</span> and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s49"></a>    <a name="section-8.4.17"></a>     <p></p>     <p class="First">CYP2C19 Inhibitors - Celexa 20 mg/day is the maximum recommended dose for patients taking concomitant CYP2C19 inhibitors because of the risk of QT prolongation (see <span class="Bold"><a href="#s15">WARNINGS</a></span>, <span class="Bold"><a href="#s95">DOSAGE AND ADMINISTRATION</a>, AND <a href="#s4">CLINICAL PHARMACOLOGY</a></span>).</p>     <p>Metoprolol - Administration of 40 mg/day Celexa for 22 days resulted in a two-fold increase in the plasma levels of the beta-adrenergic blocker metoprolol. Increased metoprolol plasma levels have been associated with decreased cardioselectivity. Coadministration of Celexa and metoprolol had no clinically significant effects on blood pressure or heart rate.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s50"></a>    <a name="section-8.4.18"></a>     <p></p>     <p class="First">Imipramine and Other Tricyclic Antidepressants (TCAs) - <span class="Italics">In vitro</span> studies suggest that citalopram is a relatively weak inhibitor of CYP2D6. Coadministration of Celexa (40 mg/day for 10 days) with the TCA imipramine (single dose of 100 mg), a substrate for CYP2D6, did not significantly affect the plasma concentrations of imipramine or citalopram. However, the concentration of the imipramine metabolite desipramine was increased by approximately 50%. The clinical significance of the desipramine change is unknown. Nevertheless, caution is indicated in the coadministration of TCAs with Celexa.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s51"></a>    <a name="section-8.4.19"></a>     <p></p>     <p class="First">Electroconvulsive Therapy (ECT) - There are no clinical studies of the combined use of electroconvulsive therapy (ECT) and Celexa.</p>    </div>   </div>   <div class="Section" data-sectioncode="34083-6">    <a name="s52"></a>   <a name="section-8.5"></a>    <p></p>    <h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>    <div class="Section" data-sectioncode="42229-5">     <a name="s53"></a>    <a name="section-8.5.1"></a>     <p></p>     <h3>Carcinogenesis</h3>     <p class="First">Citalopram was administered in the diet to NMRI/BOM strain mice and COBS WI strain rats for 18 and 24 months, respectively. There was no evidence for carcinogenicity of citalopram in mice receiving up to 240 mg/kg/day, which is equivalent to 20 times the maximum recommended human daily dose (MRHD) of 60 mg on a surface area (mg/m<span class="Sup">2</span>) basis. There was an increased incidence of small intestine carcinoma in rats receiving 8 or 24 mg/kg/day, doses which are approximately 1.3 and 4 times the MRHD, respectively, on a mg/m<span class="Sup">2</span> basis. A no-effect dose for this finding was not established. The relevance of these findings to humans is unknown.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s54"></a>    <a name="section-8.5.2"></a>     <p></p>     <h3>Mutagenesis</h3>     <p class="First">Citalopram was mutagenic in the <span class="Italics">in vitro</span> bacterial reverse mutation assay (Ames test) in 2 of 5 bacterial strains (Salmonella TA98 and TA1537) in the absence of metabolic activation. It was clastogenic in the <span class="Italics">in vitro</span> Chinese hamster lung cell assay for chromosomal aberrations in the presence and absence of metabolic activation. Citalopram was not mutagenic in the <span class="Italics">in vitro</span> mammalian forward gene mutation assay (HPRT) in mouse lymphoma cells or in a coupled <span class="Italics">in vitro/in vivo</span> unscheduled DNA synthesis (UDS) assay in rat liver. It was not clastogenic in the <span class="Italics">in vitro</span> chromosomal aberration assay in human lymphocytes or in two <span class="Italics">in vivo</span> mouse micronucleus assays.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s55"></a>    <a name="section-8.5.3"></a>     <p></p>     <h3>Impairment of Fertility</h3>     <p class="First">When citalopram was administered orally to 16 male and 24 female rats prior to and throughout mating and gestation at doses of 32, 48, and 72 mg/kg/day, mating was decreased at all doses, and fertility was decreased at doses ≥ 32 mg/kg/day, approximately 5 times the MRHD of 60 mg/day on a body surface area (mg/m<span class="Sup">2</span>) basis. Gestation duration was increased at 48 mg/kg/day, approximately 8 times the MRHD.</p>    </div>   </div>   <div class="Section" data-sectioncode="42228-7">    <a name="s56"></a>   <a name="section-8.6"></a>    <p></p>    <h2>Pregnancy</h2>    <div class="Section" data-sectioncode="42229-5">     <a name="s57"></a>    <a name="section-8.6.1"></a>     <p></p>     <h3>Pregnancy Category C</h3>     <p class="First">In animal reproduction studies, citalopram has been shown to have adverse effects on embryo/fetal and postnatal development, including teratogenic effects, when administered at doses greater than human therapeutic doses.</p>     <p>In two rat embryo/fetal development studies, oral administration of citalopram (32, 56, or 112 mg/kg/day) to pregnant animals during the period of organogenesis resulted in decreased embryo/fetal growth and survival and an increased incidence of fetal abnormalities (including cardiovascular and skeletal defects) at the high dose, which is approximately 18 times the MRHD of 60 mg/day on a body surface area (mg/m<span class="Sup">2</span>) basis. This dose was also associated with maternal toxicity (clinical signs, decreased body weight gain). The developmental, no-effect dose of 56 mg/kg/day is approximately 9 times the MRHD on a mg/m<span class="Sup">2</span> basis. In a rabbit study, no adverse effects on embryo/fetal development were observed at doses of up to 16 mg/kg/day, or approximately 5 times the MRHD on a mg/m<span class="Sup">2</span> basis. Thus, teratogenic effects were observed at a maternally toxic dose in the rat and were not observed in the rabbit.</p>     <p>When female rats were treated with citalopram (4.8, 12.8, or 32 mg/kg/day) from late gestation through weaning, increased offspring mortality during the first 4 days after birth and persistent offspring growth retardation were observed at the highest dose, which is approximately 5 times the MRHD on a mg/m<span class="Sup">2</span> basis. The no-effect dose of 12.8 mg/kg/day is approximately 2 times the MRHD on a mg/m<span class="Sup">2</span> basis. Similar effects on offspring mortality and growth were seen when dams were treated throughout gestation and early lactation at doses ≥ 24 mg/kg/day, approximately 4 times the MRHD on a mg/m<span class="Sup">2</span> basis. A no-effect dose was not determined in that study.</p>     <p>There are no adequate and well-controlled studies in pregnant women; therefore, citalopram should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>    </div>    <div class="Section" data-sectioncode="34078-6">     <a name="s58"></a>    <a name="section-8.6.2"></a>     <p></p>     <h3>Pregnancy-Nonteratogenic Effects</h3>     <p class="First">Neonates exposed to Celexa and other SSRIs or serotonin and norepinephrine reuptake inhibitors (SNRIs), late in the third trimester, have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability, and constant crying. These features are consistent with either a direct toxic effect of SSRIs and SNRIs or, possibly, a drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with serotonin syndrome (see <span class="Bold"><a href="#s20">WARNINGS: Serotonin Syndrome</a></span>).</p>     <p>Infants exposed to SSRIs in pregnancy may have an increased risk for persistent pulmonary hypertension of the newborn (PPHN). PPHN occurs in 1- 2 per 1,000 live births in the general population and is associated with substantial neonatal morbidity and mortality. Several recent epidemiologic studies suggest a positive statistical association between SSRI use (including Celexa) in pregnancy and PPHN. Other studies do not show a significant statistical association. </p>     <p>Physicians should also note the results of a prospective longitudinal study of 201 pregnant women with a history of major depression, who were either on antidepressants or had received antidepressants less than 12 weeks prior to their last menstrual period, and were in remission. Women who discontinued antidepressant medication during pregnancy showed a significant increase in relapse of their major depression compared to those women who remained on antidepressant medication throughout pregnancy. </p>     <p>When treating a pregnant woman with Celexa, the physician should carefully consider both the potential risks of taking an SSRI, along with the established benefits of treating depression with an antidepressant. This decision can only be made on a case by case basis (see <span class="Bold"><a href="#s95">DOSAGE AND ADMINISTRATION</a></span>).</p>    </div>   </div>   <div class="Section" data-sectioncode="34079-4">    <a name="s59"></a>   <a name="section-8.7"></a>    <p></p>    <h2>Labor and Delivery</h2>    <p class="First">The effect of Celexa on labor and delivery in humans is unknown.</p>   </div>   <div class="Section" data-sectioncode="34080-2">    <a name="s60"></a>   <a name="section-8.8"></a>    <p></p>    <h2>Nursing Mothers</h2>    <p class="First">As has been found to occur with many other drugs, citalopram is excreted in human breast milk. There have been two reports of infants experiencing excessive somnolence, decreased feeding, and weight loss in association with breastfeeding from a citalopram-treated mother; in one case, the infant was reported to recover completely upon discontinuation of citalopram by its mother and in the second case, no follow-up information was available. The decision whether to continue or discontinue either nursing or Celexa therapy should take into account the risks of citalopram exposure for the infant and the benefits of Celexa treatment for the mother.</p>   </div>   <div class="Section" data-sectioncode="34081-0">    <a name="s61"></a>   <a name="section-8.9"></a>    <p></p>    <h2>Pediatric Use</h2>    <p class="First">Safety and effectiveness in the pediatric population have not been established (see <span class="Bold"><a href="#s2">BOXED WARNING</a> and <a href="#s16">WARNINGS—Clinical Worsening and Suicide Risk</a></span>). Two placebo-controlled trials in 407 pediatric patients with MDD have been conducted with Celexa, and the data were not sufficient to support a claim for use in pediatric patients. Anyone considering the use of Celexa in a child or adolescent must balance the potential risks with the clinical need.</p>    <p>Decreased appetite and weight loss have been observed in association with the use of SSRIs. Consequently, regular monitoring of weight and growth should be performed in children and adolescents treated with Celexa.</p>   </div>   <div class="Section" data-sectioncode="34082-8">    <a name="s62"></a>   <a name="section-8.10"></a>    <p></p>    <h2>Geriatric Use</h2>    <p class="First">Of 4422 patients in clinical studies of Celexa, 1357 were 60 and over, 1034 were 65 and over, and 457 were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Most elderly patients treated with Celexa in clinical trials received daily doses between 20 and 40 mg (see <span class="Bold"><a href="#s95">DOSAGE AND ADMINISTRATION</a></span>).</p>    <p>SSRIs and SNRIs, including Celexa, have been associated with cases of clinically significant hyponatremia in elderly patients, who may be at greater risk for this adverse event (see <span class="Bold"><a href="#s24">PRECAUTIONS, Hyponatremia</a></span>).</p>    <p>In two pharmacokinetic studies, citalopram AUC was increased by 23% and 30%, respectively, in subjects ≥ 60 years of age as compared to younger subjects, and its half-life was increased by 30% and 50%, respectively (see <span class="Bold"><a href="#s4">CLINICAL PHARMACOLOGY</a></span>).</p>    <p>20 mg/day is the maximum recommended dose for patients who are greater than 60 years of age (see <span class="Bold"><a href="#s15">WARNINGS</a></span> and <span class="Bold"><a href="#s95">DOSAGE AND ADMINISTRATION</a></span>).</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">ADVERSE REACTIONS</a> <div class="Section toggle-content closed" data-sectioncode="34084-4">   <a name="s63"></a>  <a name="section-9"></a>   <p></p>    <p class="First">The premarketing development program for Celexa included citalopram exposures in patients and/or normal subjects from 3 different groups of studies: 429 normal subjects in clinical pharmacology/pharmacokinetic studies; 4422 exposures from patients in controlled and uncontrolled clinical trials, corresponding to approximately 1370 patient-exposure years. There were, in addition, over 19,000 exposures from mostly open-label, European postmarketing studies. The conditions and duration of treatment with Celexa varied greatly and included (in overlapping categories) open-label and double-blind studies, inpatient and outpatient studies, fixed-dose and dose-titration studies, and short-term and long-term exposure. Adverse reactions were assessed by collecting adverse events, results of physical examinations, vital signs, weights, laboratory analyses, ECGs, and results of ophthalmologic examinations.</p>   <p>Adverse events during exposure were obtained primarily by general inquiry and recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of events into a smaller number of standardized event categories. In the tables and tabulations that follow, standard World Health Organization (WHO) terminology has been used to classify reported adverse events.</p>   <p>The stated frequencies of adverse events represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse event of the type listed. An event was considered treatment-emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation.</p>   <div class="Section" data-sectioncode="42229-5">    <a name="s64"></a>   <a name="section-9.1"></a>    <p></p>    <h2>Adverse Findings Observed in Short-Term, Placebo-Controlled Trials</h2>    <div class="Section" data-sectioncode="42229-5">     <a name="s65"></a>    <a name="section-9.1.1"></a>     <p></p>     <h3>Adverse Events Associated with Discontinuation of Treatment</h3>     <p class="First">Among 1063 depressed patients who received Celexa at doses ranging from 10 to 80 mg/day in placebo-controlled trials of up to 6 weeks in duration, 16% discontinued treatment due to an adverse event, as compared to 8% of 446 patients receiving placebo. The adverse events associated with discontinuation and considered drug-related (i.e., associated with discontinuation in at least 1% of Celexa-treated patients at a rate at least twice that of placebo) are shown in <span class="Bold"><a href="#t2">TABLE 2</a></span>. It should be noted that one patient can report more than one reason for discontinuation and be counted more than once in this table.</p>     <a name="t2"></a>     <div class="scrollingtable">     <table width="100%">       <caption>        <span>TABLE 2 Adverse Events Associated with Discontinuation of Treatment in Short-Term, Placebo-Controlled, Depression Trials</span>       </caption>       <colgroup>       <col align="left" width="34.767%" />        <col align="left" width="31.633%" />        <col align="left" width="33.600%" />       </colgroup>      <tbody class="Headless">        <tr class="First">         <td align="center" colspan="3" valign="top"><span class="Bold">Percentage of Patients Discontinuing</span></td>        </tr>        <tr>         <td align="center" colspan="3" valign="top"><span class="Bold">Due to Adverse Event</span></td>        </tr>        <tr>         <td align="justify" valign="top"></td>        <td align="center" valign="top"><span class="Bold Underline">Citalopram</span></td>        <td align="center" valign="top"><span class="Bold Underline">Placebo</span></td>        </tr>        <tr>         <td align="justify" valign="top"></td>        <td align="center" valign="top"><span class="Bold">(N=1063)</span></td>        <td align="center" valign="top"><span class="Bold">(N=446)</span></td>        </tr>        <tr>         <td align="justify" valign="top"><span class="Bold Underline">Body System/Adverse Event</span></td>        <td align="center" valign="top"></td>        <td align="center" valign="top"></td>        </tr>        <tr>         <td align="left" valign="top"><span class="Bold">General</span></td>        <td align="center" valign="top"></td>        <td align="center" valign="top"></td>        </tr>        <tr>         <td align="left" valign="top">&nbsp; &nbsp; &nbsp;Asthenia</td>        <td align="center" valign="top">1%</td>        <td align="center" valign="top">&lt;1%</td>        </tr>        <tr>         <td align="left" valign="top"><span class="Bold">Gastrointestinal Disorders</span></td>        <td align="center" valign="top"></td>        <td align="center" valign="top"></td>        </tr>        <tr>         <td align="left" valign="top">&nbsp; &nbsp; &nbsp;Nausea</td>        <td align="center" valign="top">4%</td>        <td align="center" valign="top">0%</td>        </tr>        <tr>         <td align="left" valign="top">&nbsp; &nbsp; &nbsp;Dry Mouth</td>        <td align="center" valign="top">1%</td>        <td align="center" valign="top">&lt;1%</td>        </tr>        <tr>         <td align="left" valign="top">&nbsp; &nbsp; &nbsp;Vomiting</td>        <td align="center" valign="top">1%</td>        <td align="center" valign="top">0%</td>        </tr>        <tr>         <td align="left" valign="top"><span class="Bold">Central and Peripheral</span></td>        <td align="center" valign="top"></td>        <td align="center" valign="top"></td>        </tr>        <tr>         <td align="left" valign="top"><span class="Bold">Nervous System Disorders</span></td>        <td align="center" valign="top"></td>        <td align="center" valign="top"></td>        </tr>        <tr>         <td align="left" valign="top">&nbsp; &nbsp; &nbsp;Dizziness</td>        <td align="center" valign="top">2%</td>        <td align="center" valign="top">&lt;1%</td>        </tr>        <tr>         <td align="justify" valign="top"><span class="Bold">Psychiatric Disorders</span></td>        <td align="center" valign="top"></td>        <td align="center" valign="top"></td>        </tr>        <tr>         <td align="left" valign="top">&nbsp; &nbsp; &nbsp;Insomnia</td>        <td align="center" valign="top">3%</td>        <td align="center" valign="top">1%</td>        </tr>        <tr>         <td align="left" valign="top">&nbsp; &nbsp; &nbsp;Somnolence</td>        <td align="center" valign="top">2%</td>        <td align="center" valign="top">1%</td>        </tr>        <tr class="Last">         <td align="left" valign="top">&nbsp; &nbsp; &nbsp;Agitation</td>        <td align="center" valign="top">1%</td>        <td align="center" valign="top">&lt;1%</td>        </tr>       </tbody>      </table>    </div>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s66"></a>    <a name="section-9.1.2"></a>     <p></p>     <h3>Adverse Events Occurring at an Incidence of 2% or More Among Celexa -Treated Patients</h3>     <p class="First"> <span class="Bold"><a href="#t3">Table 3</a></span> enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse events that occurred among 1063 depressed patients who received Celexa at doses ranging from 10 to 80 mg/day in placebo-controlled trials of up to 6 weeks in duration. Events included are those occurring in 2% or more of patients treated with Celexa and for which the incidence in patients treated with Celexa was greater than the incidence in placebo-treated patients.</p>     <p>The prescriber should be aware that these figures cannot be used to predict the incidence of adverse events in the course of usual medical practice where patient characteristics and other factors differ from those which prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and non-drug factors to the adverse event incidence rate in the population studied.</p>     <p>The only commonly observed adverse event that occurred in Celexa patients with an incidence of 5% or greater and at least twice the incidence in placebo patients was ejaculation disorder (primarily ejaculatory delay) in male patients (see <span class="Bold"><a href="#t3">TABLE 3</a></span>).</p>     <a name="t3"></a>     <div class="scrollingtable">     <table width="100%">       <caption>        <span>TABLE 3 Treatment-Emergent Adverse Events: Incidence in Placebo-Controlled Clinical Trials*</span>       </caption>       <colgroup>       <col align="left" width="44.352%" />        <col align="left" width="31.956%" />        <col align="left" width="23.692%" />       </colgroup>      <tfoot>        <tr class="First">         <td align="left" colspan="3" valign="top"> <p class="First Footnote">*Events reported by at least 2% of patients treated with Celexa are reported, except for the following events which had an incidence on placebo ≥ Celexa: headache, asthenia, dizziness, constipation, palpitation, vision abnormal, sleep disorder, nervousness, pharyngitis, micturition disorder, back pain.</p> </td>        </tr>        <tr>         <td align="left" colspan="3" valign="top"> <p class="First Footnote"> <span class="Sup">1</span>Denominator used was for females only (N=638 Celexa; N=252 placebo).</p> </td>        </tr>        <tr>         <td align="left" colspan="3" valign="top"> <p class="First Footnote"> <span class="Sup">2</span>Primarily ejaculatory delay.</p> </td>        </tr>        <tr class="Last">         <td align="left" colspan="3" valign="top"> <p class="First Footnote"> <span class="Sup">3</span>Denominator used was for males only (N=425 Celexa; N=194 placebo).</p> </td>        </tr>       </tfoot>       <tbody class="Headless">        <tr class="First">         <td align="center" colspan="3" valign="top"><span class="Bold">(Percentage of Patients Reporting Event)</span></td>        </tr>        <tr>         <td align="justify" valign="top"></td>        <td align="center" valign="top"></td>        <td align="center" valign="top"></td>        </tr>        <tr>         <td align="justify" valign="top"><span class="Bold Underline">Body System/Adverse Event</span></td>        <td align="center" valign="top"><span class="Bold Underline">Celexa</span></td>        <td align="center" valign="top"><span class="Bold Underline">Placebo</span></td>        </tr>        <tr>         <td align="justify" valign="top"></td>        <td align="center" valign="top"><span class="Bold">(N=1063)</span></td>        <td align="center" valign="top"><span class="Bold">(N=446)</span></td>        </tr>        <tr>         <td align="justify" valign="top"><span class="Bold">Autonomic Nervous System</span></td>        <td align="center" valign="top"></td>        <td align="center" valign="top"></td>        </tr>        <tr>         <td align="justify" valign="top"><span class="Bold">Disorders</span></td>        <td align="center" valign="top"></td>        <td align="center" valign="top"></td>        </tr>        <tr>         <td align="justify" valign="top">&nbsp; &nbsp; &nbsp;Dry Mouth</td>        <td align="center" valign="top">20%</td>        <td align="center" valign="top">14%</td>        </tr>        <tr>         <td align="justify" valign="top">&nbsp; &nbsp; &nbsp;Sweating Increased</td>        <td align="center" valign="top">11%</td>        <td align="center" valign="top">9%</td>        </tr>        <tr>         <td align="justify" valign="top"><span class="Bold">Central &amp; Peripheral Nervous</span></td>        <td align="center" valign="top"></td>        <td align="center" valign="top"></td>        </tr>        <tr>         <td align="justify" valign="top"><span class="Bold">System Disorders</span></td>        <td align="center" valign="top"></td>        <td align="center" valign="top"></td>        </tr>        <tr>         <td align="justify" valign="top">&nbsp; &nbsp; &nbsp;Tremor</td>        <td align="center" valign="top">8%</td>        <td align="center" valign="top">6%</td>        </tr>        <tr>         <td align="justify" valign="top"><span class="Bold">Gastrointestinal Disorders</span></td>        <td align="center" valign="top"></td>        <td align="center" valign="top"></td>        </tr>        <tr>         <td align="justify" valign="top">&nbsp; &nbsp; &nbsp;Nausea</td>        <td align="center" valign="top">21%</td>        <td align="center" valign="top">14%</td>        </tr>        <tr>         <td align="justify" valign="top">&nbsp; &nbsp; &nbsp;Diarrhea</td>        <td align="center" valign="top">8%</td>        <td align="center" valign="top">5%</td>        </tr>        <tr>         <td align="justify" valign="top">&nbsp; &nbsp; &nbsp;Dyspepsia</td>        <td align="center" valign="top">5%</td>        <td align="center" valign="top">4%</td>        </tr>        <tr>         <td align="justify" valign="top">&nbsp; &nbsp; &nbsp;Vomiting</td>        <td align="center" valign="top">4%</td>        <td align="center" valign="top">3%</td>        </tr>        <tr>         <td align="justify" valign="top">&nbsp; &nbsp; &nbsp;Abdominal Pain</td>        <td align="center" valign="top">3%</td>        <td align="center" valign="top">2%</td>        </tr>        <tr>         <td align="justify" valign="top"><span class="Bold">General</span></td>        <td align="center" valign="top"></td>        <td align="center" valign="top"></td>        </tr>        <tr>         <td align="justify" valign="top">&nbsp; &nbsp; &nbsp;Fatigue</td>        <td align="center" valign="top">5%</td>        <td align="center" valign="top">3%</td>        </tr>        <tr>         <td align="justify" valign="top">&nbsp; &nbsp; &nbsp;Fever</td>        <td align="center" valign="top">2%</td>        <td align="center" valign="top">&lt;1%</td>        </tr>        <tr>         <td align="justify" valign="top"><span class="Bold">Musculoskeletal System</span></td>        <td align="center" valign="top"></td>        <td align="center" valign="top"></td>        </tr>        <tr>         <td align="justify" valign="top"><span class="Bold">Disorders</span></td>        <td align="center" valign="top"></td>        <td align="center" valign="top"></td>        </tr>        <tr>         <td align="justify" valign="top">&nbsp; &nbsp; &nbsp;Arthralgia</td>        <td align="center" valign="top">2%</td>        <td align="center" valign="top">1%</td>        </tr>        <tr>         <td align="justify" valign="top">&nbsp; &nbsp; &nbsp;Myalgia</td>        <td align="center" valign="top">2%</td>        <td align="center" valign="top">1%</td>        </tr>        <tr>         <td align="justify" valign="top"><span class="Bold">Psychiatric Disorders</span></td>        <td align="center" valign="top"></td>        <td align="center" valign="top"></td>        </tr>        <tr>         <td align="justify" valign="top">&nbsp; &nbsp; &nbsp;Somnolence</td>        <td align="center" valign="top">18%</td>        <td align="center" valign="top">10%</td>        </tr>        <tr>         <td align="justify" valign="top">&nbsp; &nbsp; &nbsp;Insomnia</td>        <td align="center" valign="top">15%</td>        <td align="center" valign="top">14%</td>        </tr>        <tr>         <td align="justify" valign="top">&nbsp; &nbsp; &nbsp;Anxiety</td>        <td align="center" valign="top">4%</td>        <td align="center" valign="top">3%</td>        </tr>        <tr>         <td align="justify" valign="top">&nbsp; &nbsp; &nbsp;Anorexia</td>        <td align="center" valign="top">4%</td>        <td align="center" valign="top">2%</td>        </tr>        <tr>         <td align="justify" valign="top">&nbsp; &nbsp; &nbsp;Agitation</td>        <td align="center" valign="top">3%</td>        <td align="center" valign="top">1%</td>        </tr>        <tr>         <td align="justify" valign="top">&nbsp; &nbsp; &nbsp;Dysmenorrhea<span class="Sup">1</span></td>        <td align="center" valign="top">3%</td>        <td align="center" valign="top">2%</td>        </tr>        <tr>         <td align="justify" valign="top">&nbsp; &nbsp; &nbsp;Libido Decreased</td>        <td align="center" valign="top">2%</td>        <td align="center" valign="top">&lt;1%</td>        </tr>        <tr>         <td align="justify" valign="top">&nbsp; &nbsp; &nbsp;Yawning</td>        <td align="center" valign="top">2%</td>        <td align="center" valign="top">&lt;1%</td>        </tr>        <tr>         <td align="justify" valign="top"><span class="Bold">Respiratory System Disorders</span></td>        <td align="center" valign="top"></td>        <td align="center" valign="top"></td>        </tr>        <tr>         <td align="justify" valign="top">&nbsp; &nbsp; &nbsp;Upper Respiratory Tract Infection</td>        <td align="center" valign="top">5%</td>        <td align="center" valign="top">4%</td>        </tr>        <tr>         <td align="justify" valign="top">&nbsp; &nbsp; &nbsp;Rhinitis</td>        <td align="center" valign="top">5%</td>        <td align="center" valign="top">3%</td>        </tr>        <tr>         <td align="justify" valign="top">&nbsp; &nbsp; &nbsp;Sinusitis</td>        <td align="center" valign="top">3%</td>        <td align="center" valign="top">&lt;1%</td>        </tr>        <tr>         <td align="justify" valign="top"><span class="Bold">Urogenital</span></td>        <td align="center" valign="top"></td>        <td align="center" valign="top"></td>        </tr>        <tr>         <td align="justify" valign="top">&nbsp; &nbsp; &nbsp;Ejaculation Disorder<span class="Sup">2,3</span></td>        <td align="center" valign="top">6%</td>        <td align="center" valign="top">1%</td>        </tr>        <tr class="Last">         <td align="justify" valign="top">&nbsp; &nbsp; &nbsp;Impotence<span class="Sup">3</span></td>        <td align="center" valign="top">3%</td>        <td align="center" valign="top">&lt;1%</td>        </tr>       </tbody>      </table>    </div>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s67"></a>    <a name="section-9.1.3"></a>     <p></p>     <h3>Dose Dependency of Adverse Events</h3>     <p class="First">The potential relationship between the dose of Celexa administered and the incidence of adverse events was examined in a fixed-dose study in depressed patients receiving placebo or Celexa 10, 20, 40, and 60 mg. Jonckheere's trend test revealed a positive dose response (p&lt;0.05) for the following adverse events: fatigue, impotence, insomnia, sweating increased, somnolence, and yawning.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s68"></a>    <a name="section-9.1.4"></a>     <p></p>     <h3>Male and Female Sexual Dysfunction with SSRIs</h3>     <p class="First">Although changes in sexual desire, sexual performance, and sexual satisfaction often occur as manifestations of a psychiatric disorder, they may also be a consequence of pharmacologic treatment. In particular, some evidence suggests that SSRIs can cause such untoward sexual experiences.</p>     <p>Reliable estimates of the incidence and severity of untoward experiences involving sexual desire, performance, and satisfaction are difficult to obtain, however, in part because patients and physicians may be reluctant to discuss them. Accordingly, estimates of the incidence of untoward sexual experience and performance cited in product labeling, are likely to underestimate their actual incidence.</p>     <p>The table below displays the incidence of sexual side effects reported by at least 2% of patients taking Celexa in a pool of placebo-controlled clinical trials in patients with depression.</p>     <div class="scrollingtable">     <table width="100%">       <colgroup>       <col align="left" width="49.084%" />        <col align="left" width="25.458%" />        <col align="left" width="25.458%" />       </colgroup>      <tbody class="Headless">        <tr class="First">         <td class="Botrule Lrule Rrule Toprule" align="justify" valign="top"><span class="Underline">Treatment</span></td>        <td class="Botrule Rrule Toprule" align="justify" valign="top"><span class="Underline">Celexa</span> <br />(425 males)</td>        <td class="Botrule Rrule Toprule" align="justify" valign="top"><span class="Underline">Placebo</span> <br />(194 males)</td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="justify" valign="top">Abnormal Ejaculation<br />(mostly ejaculatory delay)</td>        <td class="Botrule Rrule" align="justify" valign="top">6.1%<br />(males only)</td>        <td class="Botrule Rrule" align="justify" valign="top">1%<br />(males only)</td>        </tr>        <tr>         <td class="Botrule Lrule Rrule" align="left" valign="top">Libido Decreased</td>        <td class="Botrule Rrule" align="justify" valign="top">3.8%<br />(males only)</td>        <td class="Botrule Rrule" align="justify" valign="top">&lt;1%<br />(males only)</td>        </tr>        <tr class="Last">         <td class="Botrule Lrule Rrule" align="justify" valign="top">Impotence</td>        <td class="Botrule Rrule" align="justify" valign="top">2.8%<br />(males only)</td>        <td class="Botrule Rrule" align="justify" valign="top">&lt;1%<br />(males only)</td>        </tr>       </tbody>      </table>    </div>     <p>In female depressed patients receiving Celexa, the reported incidence of decreased libido and anorgasmia was 1.3% (n=638 females) and 1.1% (n=252 females), respectively.</p>     <p>There are no adequately designed studies examining sexual dysfunction with citalopram treatment.</p>     <p>Priapism has been reported with all SSRIs.</p>     <p>While it is difficult to know the precise risk of sexual dysfunction associated with the use of SSRIs, physicians should routinely inquire about such possible side effects.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s69"></a>    <a name="section-9.1.5"></a>     <p></p>     <h3>Vital Sign Changes</h3>     <p class="First">Celexa and placebo groups were compared with respect to (1) mean change from baseline in vital signs (pulse, systolic blood pressure, and diastolic blood pressure) and (2) the incidence of patients meeting criteria for potentially clinically significant changes from baseline in these variables. These analyses did not reveal any clinically important changes in vital signs associated with Celexa treatment. In addition, a comparison of supine and standing vital sign measures for Celexa and placebo treatments indicated that Celexa treatment is not associated with orthostatic changes.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s70"></a>    <a name="section-9.1.6"></a>     <p></p>     <h3>Weight Changes</h3>     <p class="First">Patients treated with Celexa in controlled trials experienced a weight loss of about 0.5 kg compared to no change for placebo patients.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s71"></a>    <a name="section-9.1.7"></a>     <p></p>     <h3>Laboratory Changes</h3>     <p class="First">Celexa and placebo groups were compared with respect to (1) mean change from baseline in various serum chemistry, hematology, and urinalysis variables, and (2) the incidence of patients meeting criteria for potentially clinically significant changes from baseline in these variables. These analyses revealed no clinically important changes in laboratory test parameters associated with Celexa treatment.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s72"></a>    <a name="section-9.1.8"></a>     <p></p>     <h3>ECG Changes</h3>     <p class="First">In a thorough QT study, Celexa was found to be associated with a dose-dependent increase in the QTc interval (see <span class="Bold"><a href="#e18">WARNINGS - QT-Prolongation and Torsade de Pointes</a>)</span>.</p>     <p>Electrocardiograms from Celexa (N=802) and placebo (N=241) groups were compared with respect to outliers defined as subjects with QTc changes over 60 msec from baseline or absolute values over 500 msec post-dose, and subjects with heart rate increases to over 100 bpm or decreases to less than 50 bpm with a 25% change from baseline (tachycardic or bradycardic outliers, respectively). In the Celexa group 1.9% of the patients had a change from baseline in QTcF &gt;60 msec compared to 1.2% of the patients in the placebo group. None of the patients in the placebo group had a post-dose QTcF &gt;500 msec compared to 0.5% of the patients in the Celexa group. The incidence of tachycardic outliers was 0.5% in the Celexa group and 0.4% in the placebo group. The incidence of bradycardic outliers was 0.9% in the Celexa group and 0.4% in the placebo group.</p>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s73"></a>   <a name="section-9.2"></a>    <p></p>    <h2>Other Events Observed During the Premarketing Evaluation of Celexa (citalopram HBr)</h2>    <p class="First">Following is a list of WHO terms that reflect treatment-emergent adverse events, as defined in the introduction to the <span class="Bold"><a href="#s63">ADVERSE REACTIONS</a></span> section, reported by patients treated with Celexa at multiple doses in a range of 10 to 80 mg/day during any phase of a trial within the premarketing database of 4422 patients. All reported events are included except those already listed in <span class="Bold"><a href="#t3">Table 3</a></span> or elsewhere in labeling, those events for which a drug cause was remote, those event terms which were so general as to be uninformative, and those occurring in only one patient. It is important to emphasize that, although the events reported occurred during treatment with Celexa, they were not necessarily caused by it.</p>    <p>Events are further categorized by body system and listed in order of decreasing frequency according to the following definitions: frequent adverse events are those occurring on one or more occasions in at least 1/100 patients; infrequent adverse events are those occurring in less than 1/100 patients but at least 1/1000 patients; rare events are those occurring in fewer than 1/1000 patients.</p>    <div class="Section" data-sectioncode="42229-5">     <a name="s74"></a>    <a name="section-9.2.1"></a>     <p></p>     <p class="First"> <span class="Bold">Cardiovascular</span> - <span class="Italics">Frequent:</span> tachycardia, postural hypotension, hypotension. <span class="Italics">Infrequent:</span> hypertension, bradycardia, edema (extremities), angina pectoris, extrasystoles, cardiac failure, flushing, myocardial infarction, cerebrovascular accident, myocardial ischemia. <span class="Italics">Rare:</span> transient ischemic attack, phlebitis, atrial fibrillation, cardiac arrest, bundle branch block.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s75"></a>    <a name="section-9.2.2"></a>     <p></p>     <p class="First"> <span class="Bold">Central and Peripheral Nervous System Disorders</span> - <span class="Italics">Frequent:</span> paresthesia, migraine. <span class="Italics">Infrequent:</span> hyperkinesia, vertigo, hypertonia, extrapyramidal disorder, leg cramps, involuntary muscle contractions, hypokinesia, neuralgia, dystonia, abnormal gait, hypesthesia, ataxia. <span class="Italics">Rare:</span> abnormal coordination, hyperesthesia, ptosis, stupor.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s76"></a>    <a name="section-9.2.3"></a>     <p></p>     <p class="First"> <span class="Bold">Endocrine Disorders</span> - <span class="Italics">Rare:</span> hypothyroidism, goiter, gynecomastia.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s77"></a>    <a name="section-9.2.4"></a>     <p></p>     <p class="First"> <span class="Bold">Gastrointestinal Disorders</span> - <span class="Italics">Frequent:</span> saliva increased, flatulence. <span class="Italics">Infrequent:</span> gastritis, gastroenteritis, stomatitis, eructation, hemorrhoids, dysphagia, teeth grinding, gingivitis, esophagitis. <span class="Italics">Rare:</span> colitis, gastric ulcer, cholecystitis, cholelithiasis, duodenal ulcer, gastroesophageal reflux, glossitis, jaundice, diverticulitis, rectal hemorrhage, hiccups.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s78"></a>    <a name="section-9.2.5"></a>     <p></p>     <p class="First"> <span class="Bold">General</span> - <span class="Italics">Infrequent:</span> hot flushes, rigors, alcohol intolerance, syncope, influenza-like symptoms. <span class="Italics">Rare:</span> hayfever.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s79"></a>    <a name="section-9.2.6"></a>     <p></p>     <p class="First"> <span class="Bold">Hemic and Lymphatic Disorders</span> - <span class="Italics">Infrequent:</span> purpura, anemia, epistaxis, leukocytosis, leucopenia, lymphadenopathy. <span class="Italics">Rare:</span> pulmonary embolism, granulocytopenia, lymphocytosis, lymphopenia, hypochromic anemia, coagulation disorder, gingival bleeding.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s80"></a>    <a name="section-9.2.7"></a>     <p></p>     <p class="First"> <span class="Bold">Metabolic and Nutritional Disorders</span> - <span class="Italics">Frequent:</span> decreased weight, increased weight. <span class="Italics">Infrequent:</span> increased hepatic enzymes, thirst, dry eyes, increased alkaline phosphatase, abnormal glucose tolerance. <span class="Italics">Rare:</span> bilirubinemia, hypokalemia, obesity, hypoglycemia, hepatitis, dehydration.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s81"></a>    <a name="section-9.2.8"></a>     <p></p>     <p class="First"> <span class="Bold">Musculoskeletal System Disorders</span> - <span class="Italics">Infrequent:</span> arthritis, muscle weakness, skeletal pain. <span class="Italics">Rare:</span> bursitis, osteoporosis.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s82"></a>    <a name="section-9.2.9"></a>     <p></p>     <p class="First"> <span class="Bold">Psychiatric Disorders</span> - <span class="Italics">Frequent:</span> impaired concentration, amnesia, apathy, depression, increased appetite, aggravated depression, suicide attempt, confusion. <span class="Italics">Infrequent:</span> increased libido, aggressive reaction, paroniria, drug dependence, depersonalization, hallucination, euphoria, psychotic depression, delusion, paranoid reaction, emotional lability, panic reaction, psychosis. <span class="Italics">Rare:</span> catatonic reaction, melancholia.</p>     <p> <span class="Bold">Reproductive Disorders/Female*</span> - <span class="Italics">Frequent:</span> amenorrhea. <span class="Italics">Infrequent:</span> galactorrhea, breast pain, breast enlargement, vaginal hemorrhage.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s83"></a>    <a name="section-9.2.10"></a>     <p></p>     <p class="First">*% based on female subjects only: 2955</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s84"></a>    <a name="section-9.2.11"></a>     <p></p>     <p class="First"> <span class="Bold">Respiratory System Disorders</span> - <span class="Italics">Frequent:</span> coughing. <span class="Italics">Infrequent:</span> bronchitis, dyspnea, pneumonia. <span class="Italics">Rare:</span> asthma, laryngitis, bronchospasm, pneumonitis, sputum increased.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s85"></a>    <a name="section-9.2.12"></a>     <p></p>     <p class="First"> <span class="Bold">Skin and Appendages Disorders</span> - <span class="Italics">Frequent:</span> rash, pruritus. <span class="Italics">Infrequent:</span> photosensitivity reaction, urticaria, acne, skin discoloration, eczema, alopecia, dermatitis, skin dry, psoriasis. <span class="Italics">Rare:</span> hypertrichosis, decreased sweating, melanosis, keratitis, cellulitis, pruritus ani.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s86"></a>    <a name="section-9.2.13"></a>     <p></p>     <p class="First"> <span class="Bold">Special Senses</span> - <span class="Italics">Frequent:</span> accommodation abnormal, taste perversion. <span class="Italics">Infrequent:</span> tinnitus, conjunctivitis, eye pain. <span class="Italics">Rare:</span> mydriasis, photophobia, diplopia, abnormal lacrimation, cataract, taste loss.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s87"></a>    <a name="section-9.2.14"></a>     <p></p>     <p class="First"> <span class="Bold">Urinary System Disorders</span> - <span class="Italics">Frequent:</span> polyuria. <span class="Italics">Infrequent:</span> micturition frequency, urinary incontinence, urinary retention, dysuria. <span class="Italics">Rare:</span> facial edema, hematuria, oliguria, pyelonephritis, renal calculus, renal pain.</p>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s88"></a>   <a name="section-9.3"></a>    <p></p>    <h2>Other Events Observed During the Postmarketing Evaluation of Celexa (citalopram HBr)</h2>    <p class="First">It is estimated that over 30 million patients have been treated with Celexa since market introduction. Although no causal relationship to Celexa treatment has been found, the following adverse events have been reported to be temporally associated with Celexa treatment, and have not been described elsewhere in labeling: acute renal failure, akathisia, allergic reaction, anaphylaxis, angioedema, choreoathetosis, chest pain, delirium, dyskinesia, ecchymosis, epidermal necrolysis, erythema multiforme, gastrointestinal hemorrhage, angle closure glaucoma, grand mal convulsions, hemolytic anemia, hepatic necrosis, myoclonus, nystagmus, pancreatitis, priapism, prolactinemia, prothrombin decreased, QT prolonged, rhabdomyolysis, spontaneous abortion, thrombocytopenia, thrombosis, ventricular arrhythmia, torsade de pointes, and withdrawal syndrome.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">DRUG ABUSE AND DEPENDENCE</a> <div class="Section toggle-content closed" data-sectioncode="42227-9">   <a name="s89"></a>  <a name="section-10"></a>   <p></p>    <div class="Section" data-sectioncode="34085-1">    <a name="s90"></a>   <a name="section-10.1"></a>    <p></p>    <h2>Controlled Substance Class</h2>    <p class="First">Celexa (citalopram HBr) is not a controlled substance.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s91"></a>   <a name="section-10.2"></a>    <p></p>    <h2>Physical and Psychological Dependence</h2>    <p class="First">Animal studies suggest that the abuse liability of Celexa is low. Celexa has not been systematically studied in humans for its potential for abuse, tolerance, or physical dependence. The premarketing clinical experience with Celexa did not reveal any drug-seeking behavior. However, these observations were not systematic and it is not possible to predict, on the basis of this limited experience, the extent to which a CNS-active drug will be misused, diverted, and/or abused once marketed. Consequently, physicians should carefully evaluate Celexa patients for history of drug abuse and follow such patients closely, observing them for signs of misuse or abuse (e.g., development of tolerance, incrementations of dose, drug-seeking behavior).</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">OVERDOSAGE</a> <div class="Section toggle-content closed" data-sectioncode="34088-5">   <a name="s92"></a>  <a name="section-11"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="s93"></a>   <a name="section-11.1"></a>    <p></p>    <h2>Human Experience</h2>    <p class="First">In clinical trials of citalopram, there were reports of citalopram overdose, including overdoses of up to 2000mg, with no associated fatalities. During the postmarketing evaluation of citalopram, Celexa overdoses, including overdoses of up to 6000 mg, have been reported. As with other SSRIs, a fatal outcome in a patient who has taken an overdose of citalopram has been rarely reported.</p>    <p>Symptoms most often accompanying citalopram overdose, alone or in combination with other drugs and/or alcohol, included dizziness, sweating, nausea, vomiting, tremor, somnolence, and sinus tachycardia. In more rare cases, observed symptoms included amnesia, confusion, coma, convulsions, hyperventilation, cyanosis, rhabdomyolysis, and ECG changes (including QTc prolongation, nodal rhythm, ventricular arrhythmia, and very rare cases of torsade de pointes). Acute renal failure has been very rarely reported accompanying overdose.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s94"></a>   <a name="section-11.2"></a>    <p></p>    <h2>Management of Overdose</h2>    <p class="First">Establish and maintain an airway to ensure adequate ventilation and oxygenation. Gastric evacuation by lavage and use of activated charcoal should be considered. Careful observation and cardiac and vital sign monitoring are recommended, along with general symptomatic and supportive care. Due to the large volume of distribution of citalopram, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit. There are no specific antidotes for Celexa.</p>    <p>In managing overdosage, consider the possibility of multiple-drug involvement. The physician should consider contacting a poison control center for additional information on the treatment of any overdose.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">DOSAGE AND ADMINISTRATION</a> <div class="Section toggle-content closed" data-sectioncode="34068-7">   <a name="s95"></a>  <a name="section-12"></a>   <p></p>    <p class="First">Celexa should be administered once daily, in the morning or evening, with or without food.</p>   <div class="Section" data-sectioncode="42229-5">    <a name="s96"></a>   <a name="section-12.1"></a>    <p></p>    <h2>Initial Treatment</h2>    <p class="First">Celexa (citalopram HBr) should be administered at an initial dose of 20 mg once daily, with an increase to a maximum dose of 40 mg/day at an interval of no less than one week. Doses above 40 mg/day are not recommended due to the risk of QT prolongation. Additionally, the only study pertinent to dose response for effectiveness did not demonstrate an advantage for the 60 mg/day dose over the 40 mg/day dose. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s97"></a>   <a name="section-12.2"></a>    <p></p>    <h2>Special Populations</h2>    <p class="First">20 mg/day is the maximum recommended dose for patients who are greater than 60 years of age, patients with hepatic impairment, and for CYP2C19 poor metabolizers or those patients taking cimetidine or another CYP2C19 inhibitor. (see <span class="Bold"><a href="#s15">WARNINGS</a>)</span> </p>    <p> No dosage adjustment is necessary for patients with mild or moderate renal impairment. Celexa should be used with caution in patients with severe renal impairment.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s98"></a>   <a name="section-12.3"></a>    <p></p>    <h2>Treatment of Pregnant Women During the Third Trimester</h2>    <p class="First">Neonates exposed to Celexa and other SSRIs or SNRIs, late in the third trimester, have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding (see <span class="Bold"><a href="#s21">PRECAUTIONS</a></span>). When treating pregnant women with Celexa during the third trimester, the physician should carefully consider the potential risks and benefits of treatment.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s99"></a>   <a name="section-12.4"></a>    <p></p>    <h2>Maintenance Treatment</h2>    <p class="First">It is generally agreed that acute episodes of depression require several months or longer of sustained pharmacologic therapy. Systematic evaluation of Celexa in two studies has shown that its antidepressant efficacy is maintained for periods of up to 24 weeks following 6 or 8 weeks of initial treatment (32 weeks total). In one study, patients were assigned randomly to placebo or to the same dose of Celexa (20-60 mg/day) during maintenance treatment as they had received during the acute stabilization phase, while in the other study, patients were assigned randomly to continuation of Celexa 20 or 40 mg/day, or placebo, for maintenance treatment. In the latter study, the rates of relapse to depression were similar for the two dose groups (see <span class="Bold"><a href="#s11">Clinical Trials</a></span> under <span class="Bold"><a href="#s4">CLINICAL PHARMACOLOGY</a></span>). Based on these limited data, it is not known whether the dose of citalopram needed to maintain euthymia is identical to the dose needed to induce remission. If adverse reactions are bothersome, a decrease in dose to 20 mg/day can be considered.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s100"></a>   <a name="section-12.5"></a>    <p></p>    <h2>Discontinuation of Treatment with Celexa</h2>    <p class="First">Symptoms associated with discontinuation of Celexa and other SSRIs and SNRIs have been reported (see <span class="Bold"><a href="#s21">PRECAUTIONS</a></span>). Patients should be monitored for these symptoms when discontinuing treatment. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s101"></a>   <a name="section-12.6"></a>    <p></p>    <h2>Switching a Patient To or From a Monoamine Oxidase Inhibitor (MAOI) Intended to Treat Psychiatric Disorders</h2>    <p class="First">At least 14 days should elapse between discontinuation of an MAOI intended to treat psychiatric disorders and initiation of therapy with Celexa. Conversely, at least 14 days should be allowed after stopping Celexa before starting an MAOI intended to treat psychiatric disorders (see <span class="Bold"><a href="#s14">CONTRAINDICATIONS</a></span>).</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="e101"></a>   <a name="section-12.7"></a>    <p></p>    <h2>Use of Celexa with Other MAOIs, Such as Linezolid or Methylene Blue</h2>    <p class="First">Do not start Celexa in a patient who is being treated with linezolid or intravenous methylene blue because there is an increased risk of serotonin syndrome. In a patient who requires more urgent treatment of a psychiatric condition, other interventions, including hospitalization, should be considered (see <span class="Bold"><a href="#s14">CONTRAINDICATIONS</a></span>).</p>    <p>In some cases, a patient already receiving Celexa therapy may require urgent treatment with linezolid or intravenous methylene blue. If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue treatment are judged to outweigh the risks of serotonin syndrome in a particular patient, Celexa should be stopped promptly, and linezolid or intravenous methylene blue can be administered. The patient should be monitored for symptoms of serotonin syndrome for 2 weeks or until 24 hours after the last dose of linezolid or intravenous methylene blue, whichever comes first. Therapy with Celexa may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue (see <span class="Bold"><a href="#s15">WARNINGS</a></span>).</p>    <p>The risk of administering methylene blue by non-intravenous routes (such as oral tablets or by local injection) or in intravenous doses much lower than 1 mg/kg with Celexa is unclear. The clinician should, nevertheless, be aware of the possibility of emergent symptoms of serotonin syndrome with such use (see <span class="Bold"><a href="#s15">WARNINGS</a></span>).</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">HOW SUPPLIED</a> <div class="Section toggle-content closed" data-sectioncode="34069-5">   <a name="s102"></a>  <a name="section-13"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="s103"></a>   <a name="section-13.1"></a>    <p></p>    <h2>Tablets:</h2>    <p class="First">10 mg&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Bottle of 100&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;NDC # 0456-4010-01</p>    <p>Beige, oval, film-coated.</p>    <p>Imprint on one side with &quot;FP&quot;. Imprint on the other side with &quot;10 mg&quot;.</p>    <p>20 mg &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Bottle of 100&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;NDC # 0456-4020-01</p>    <p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;10 x 10 Unit Dose&nbsp; &nbsp; &nbsp; &nbsp;NDC # 0456-4020-63</p>    <p>Pink, oval, scored, film-coated.</p>    <p>Imprint on scored side with &quot;F&quot; on the left side and &quot;P&quot; on the right side.</p>    <p>Imprint on the non-scored side with &quot;20 mg&quot;.</p>    <p>40 mg &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Bottle of 100&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;NDC # 0456-4040-01</p>    <p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;10 x 10 Unit Dose&nbsp; &nbsp; &nbsp; &nbsp;NDC # 0456-4040-63</p>    <p>White, oval, scored, film-coated.</p>    <p>Imprint on scored side with &quot;F&quot; on the left side and &quot;P&quot; on the right side.</p>    <p>Imprint on the non-scored side with &quot;40 mg&quot;.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s104"></a>   <a name="section-13.2"></a>    <p></p>    <p class="First">Store at 25&deg;C (77&deg;F); excursions permitted to 15 - 30&deg;C (59-86&deg;F).</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">ANIMAL TOXICOLOGY</a> <div class="Section toggle-content closed" data-sectioncode="34091-9">   <a name="s105"></a>  <a name="section-14"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="s106"></a>   <a name="section-14.1"></a>    <p></p>    <h2>Retinal Changes in Rats</h2>    <p class="First">Pathologic changes (degeneration/atrophy) were observed in the retinas of albino rats in the 2-year carcinogenicity study with citalopram. There was an increase in both incidence and severity of retinal pathology in both male and female rats receiving 80 mg/kg/day (13 times the maximum recommended daily human dose of 60 mg on a mg/m<span class="Sup">2</span> basis). Similar findings were not present in rats receiving 24 mg/kg/day for two years, in mice treated for 18 months at doses up to 240 mg/kg/day, or in dogs treated for one year at doses up to 20 mg/kg/day (4, 20, and 10 times, respectively, the maximum recommended daily human dose on a mg/m<span class="Sup">2</span> basis).</p>    <p>Additional studies to investigate the mechanism for this pathology have not been performed, and the potential significance of this effect in humans has not been established.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s107"></a>   <a name="section-14.2"></a>    <p></p>    <h2>Cardiovascular Changes in Dogs</h2>    <p class="First">In a one-year toxicology study, 5 of 10 beagle dogs receiving oral doses of 8 mg/kg/day (4 times the maximum recommended daily human dose of 60 mg on a mg/m<span class="Sup">2</span> basis) died suddenly between weeks 17 and 31 following initiation of treatment. Although appropriate data from that study are not available to directly compare plasma levels of citalopram (CT) and its metabolites, demethylcitalopram (DCT) and didemethylcitalopram (DDCT), to levels that have been achieved in humans, pharmacokinetic data indicate that the relative dog-to-human exposure was greater for the metabolites than for citalopram. Sudden deaths were not observed in rats at doses up to 120 mg/kg/day, which produced plasma levels of CT, DCT, and DDCT similar to those observed in dogs at doses of 8 mg/kg/day. A subsequent intravenous dosing study demonstrated that in beagle dogs, DDCT caused QT prolongation, a known risk factor for the observed outcome in dogs. This effect occurred in dogs at doses producing peak DDCT plasma levels of 810 to 3250 nM (39-155 times the mean steady state DDCT plasma level measured at the maximum recommended human daily dose of 60 mg). In dogs, peak DDCT plasma concentrations are approximately equal to peak CT plasma concentrations, whereas in humans, steady state DDCT plasma concentrations are less than 10% of steady state CT plasma concentrations. Assays of DDCT plasma concentrations in 2020 citalopram-treated individuals demonstrated that DDCT levels rarely exceeded 70 nM; the highest measured level of DDCT in human overdose was 138 nM. While DDCT is ordinarily present in humans at lower levels than in dogs, it is unknown whether there are individuals who may achieve higher DDCT levels. The possibility that DCT, a principal metabolite in humans, may prolong the QT interval in dogs has not been directly examined because DCT is rapidly converted to DDCT in that species.</p>    <p>Forest Pharmaceuticals, Inc.<br />Subsidiary of Forest Laboratories, Inc.<br />St. Louis, MO 63045 USA</p>    <p>Licensed from H. Lundbeck A/S<br />Rev. July 2014</p>    <p>&copy; 2009, 2011, 2012, 2013, 2014 Forest Laboratories, Inc.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">Medication Guide</a> <div class="Section toggle-content closed" data-sectioncode="42231-1">   <a name="s109"></a>  <a name="section-15"></a>   <p></p>    <p class="First">Celexa<span class="Sup">&reg;</span> (se-lek-sa)</p>   <p>(citalopram hydrobromide)</p>   <p>Tablets</p>   <p>Read the Medication Guide that comes with Celexa before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or treatment. Talk with your healthcare provider if there is something you do not understand or want to learn more about.</p>   <p> <a name="p01"></a><span class="Bold">What is the most important information I should know about Celexa?</span> </p>   <p>Celexa and other antidepressant medicines may cause serious side effects, including:</p>   <p> <span class="Bold">1. Suicidal thoughts or actions:</span> </p>   <ul class="Disc">    <li> <span class="Bold">Celexa and other antidepressant medicines may increase suicidal thoughts or actions</span> in some children, teenagers, or young adults within the <span class="Bold">first few months of treatment or when the dose is changed.</span> </li>    <li>Depression or other serious mental illnesses are the most important causes of suicidal thoughts or actions.</li>    <li>Watch for these changes and call your healthcare provider right away if you notice:    <ul class="Disc">      <li>New or sudden changes in mood, behavior, actions, thoughts, or feelings, especially if severe.</li>      <li>Pay particular attention to such changes when Celexa is started or when the dose is changed.</li>     </ul> </li>   </ul>   <p>Keep all follow-up visits with your healthcare provider and call between visits if you are worried about symptoms.</p>   <p> <span class="Bold">Call your healthcare provider right away if you have any of the following symptoms, or call 911 if an emergency, especially if they are new, worse, or worry you:</span> </p>   <ul class="Disc">    <li>attempts to commit suicide</li>    <li>acting on dangerous impulses</li>    <li>acting aggressive or violent</li>    <li>thoughts about suicide or dying</li>    <li>new or worse depression</li>    <li>new or worse anxiety or panic attacks</li>    <li>feeling agitated, restless, angry or irritable</li>    <li>trouble sleeping</li>    <li>an increase in activity or talking more than what is normal for you</li>    <li>other unusual changes in behavior or mood</li>   </ul>   <p> <span class="Bold">Call your healthcare provider right away if you have any of the following symptoms, or call 911 if an emergency. Celexa may be associated with these serious side effects:</span> </p>   <p> <span class="Bold">2. Changes in the electrical activity of your heart (QT prolongation&nbsp;and Torsade de Pointes).</span> </p>   <p>This condition can be life threatening. The symptoms may include:</p>   <ul class="Disc">    <li>chest pain</li>    <li>fast or slow heartbeat</li>    <li>shortness of breath</li>    <li>dizziness or fainting</li>   </ul>   <p> <span class="Bold">3. Serotonin Syndrome. This condition can be life-threatening and may include</span>:</p>   <ul class="Disc">    <li>agitation, hallucinations, coma or other changes in mental status</li>    <li>coordination problems or muscle twitching (overactive reflexes)</li>    <li>racing heartbeat, high or low blood pressure</li>    <li>sweating or fever</li>    <li>nausea, vomiting, or diarrhea</li>    <li>muscle rigidity</li>   </ul>   <p> <span class="Bold">4. Severe allergic reactions:</span> </p>   <ul class="Disc">    <li> trouble breathing</li>    <li> swelling of the face, tongue, eyes or mouth</li>    <li>rash, itchy welts (hives) or blisters, alone or with fever or joint pain</li>   </ul>   <p> <span class="Bold">5. Abnormal bleeding</span>: Celexa and other antidepressant medicines may increase your risk of bleeding or bruising, especially if you take the blood thinner warfarin (Coumadin<span class="Sup">&reg;</span>, Jantoven<span class="Sup">&reg;</span>), a non-steroidal anti-inflammatory drug (NSAIDs, like ibuprofen or naproxen), or aspirin.</p>   <p> <span class="Bold">6. Seizures or convulsions</span> </p>   <p> <span class="Bold">7. Manic episodes:</span> </p>   <ul class="Disc">    <li>greatly increased energy</li>    <li>severe trouble sleeping</li>    <li>racing thoughts</li>    <li>reckless behavior</li>    <li>unusually grand ideas</li>    <li>excessive happiness or irritability</li>    <li>talking more or faster than usual</li>   </ul>   <p> <span class="Bold">8. Changes in appetite or weight.</span> Children and adolescents should have height and weight monitored during treatment.</p>   <p> <span class="Bold">9. Low salt (sodium) levels in the blood.</span> Elderly people may be at greater risk for this. Symptoms may include: </p>   <ul class="Disc">    <li>headache</li>    <li>weakness or feeling unsteady</li>    <li>confusion, problems concentrating or thinking or memory problems</li>   </ul>   <p> <span class="Bold">10. Visual problems</span> </p>   <ul class="Disc">    <li>eye pain</li>    <li>changes in vision</li>    <li>swelling or redness in or around the eye</li>   </ul>   <p>Only some people are at risk for these problems. You may want to undergo an eye examination to see if you are at risk and receive preventative treatment if you are. </p>   <p> <span class="Bold">Do not stop Celexa without first talking to your healthcare provider</span>. Stopping Celexa too quickly may cause serious symptoms including:</p>   <ul class="Disc">    <li>anxiety, irritability, high or low mood, feeling restless or changes in sleep habits</li>    <li>headache, sweating, nausea, dizziness</li>    <li>electric shock-like sensations, shaking, confusion</li>   </ul>   <p> <span class="Bold">What is Celexa?</span> </p>   <p>Celexa is a prescription medicine used to treat depression. It is important to talk with your healthcare provider about the risks of treating depression and also the risks of not treating it. You should discuss all treatment choices with your healthcare provider. Celexa is also used to treat:</p>   <ul class="Disc">    <li>Major Depressive Disorder (MDD)</li>   </ul>   <p>Talk to your healthcare provider if you do not think that your condition is getting better with Celexa treatment.</p>   <p> <span class="Bold">Who should not take Celexa?</span> </p>   <p>Do not take Celexa if you:</p>   <ul class="Disc">    <li>are allergic to citalopram hydrobromide or escitalopram oxalate or any of the ingredients in Celexa. See the end of this Medication Guide for a complete list of ingredients in Celexa.</li>    <li>take a monoamine oxidase inhibitor (MAOI). Ask your healthcare provider or pharmacist if you are not sure if you take an MAOI, including the antibiotic linezolid.</li>    <li>Do not take an MAOI within 2 weeks of stopping Celexa unless directed to do so by your physician.</li>    <li>Do not start Celexa if you stopped taking an MAOI in the last 2 weeks unless directed to do so by your physician.<br /> <br /> <span class="Bold">People who take Celexa close in time to an MAOI may have serious or even life-threatening side effects. Get medical help right away if you have any of these symptoms:</span>     <ul class="Disc">      <li>high fever</li>      <li>uncontrolled muscle spasms</li>      <li>stiff muscles</li>      <li>rapid changes in heart rate or blood pressure</li>      <li>confusion</li>      <li>loss of consciousness (pass out)</li>     </ul> </li>    <li> <span class="Bold">take the antipsychotic medicine pimozide (Orap</span><span class="Sup">&reg;</span><span class="Bold">) because this can cause serious heart problems.</span> </li>    <li> <span class="Bold">have a heart problem including congenital long QT syndrome</span> </li>   </ul>   <p> <span class="Bold">What should I tell my healthcare provider before taking Celexa? Ask if you are not sure.</span> </p>   <p>Before starting Celexa, tell your healthcare provider if you</p>   <ul class="Disc">    <li>Are taking certain drugs such as:    <ul class="Disc">      <li>Medicines for heart problems</li>      <li>Medicines that lower your potassium or magnesium levels in your body</li>      <li>Cimetidine</li>      <li>Triptans used to treat migraine headache</li>      <li>Medicines used to treat mood, anxiety, psychotic or thought disorders, including tricyclics, lithium, SSRIs, SNRIs, or antipsychotics</li>      <li>Tramadol</li>      <li>Over-the-counter supplements such as tryptophan or St. John's Wort</li>     </ul> </li>    <li>have liver problems</li>    <li>have kidney problems</li>    <li>have heart problems</li>    <li>have or had seizures or convulsions</li>    <li>have bipolar disorder or mania</li>    <li>have low sodium levels in your blood</li>    <li>have a history of a stroke</li>    <li>have high blood pressure</li>    <li>have or had bleeding problems</li>    <li>are pregnant or plan to become pregnant. It is not known if Celexa will harm your unborn baby. Talk to your healthcare provider about the benefits and risks of treating depression during pregnancy</li>    <li>are breast-feeding or plan to breast-feed. Some Celexa may pass into your breast milk. Talk to your healthcare provider about the best way to feed your baby while taking Celexa.</li>   </ul>   <p>Tell your healthcare provider about all the medicines that you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Celexa and some medicines may interact with each other, may not work as well, or may cause serious side effects.</p>   <p>Your healthcare provider or pharmacist can tell you if it is safe to take Celexa with your other medicines. Do not start or stop any medicine while taking Celexa without talking to your healthcare provider first.</p>   <div class="scrollingtable">   <table width="100%">     <colgroup>     <col align="left" width="100.000%" />     </colgroup>    <tbody class="Headless">      <tr class="First Last">       <td class="Botrule Lrule Rrule Toprule" align="left" valign="top">If you take Celexa, you should not take any other medicines that contain citalopram hydrobromide or escitalopram oxalate including: Lexapro.</td>      </tr>     </tbody>    </table>  </div>   <p> <span class="Bold">How should I take Celexa?</span> </p>   <ul class="Disc">    <li>Take Celexa exactly as prescribed. Your healthcare provider may need to change the dose of Celexa until it is the right dose for you.</li>    <li>Celexa may be taken with or without food.</li>    <li>If you miss a dose of Celexa, take the missed dose as soon as you remember. If it is almost time for the next dose, skip the missed dose and take your next dose at the regular time. Do not take two doses of Celexa at the same time.</li>    <li>If you take too much Celexa, call your healthcare provider or poison control center right away, or get emergency treatment.</li>   </ul>   <p> <span class="Bold">What should I avoid while taking Celexa?</span> </p>   <p>Celexa can cause sleepiness or may affect your ability to make decisions, think clearly, or react quickly. You should not drive, operate heavy machinery, or do other dangerous activities until you know how Celexa affects you. Do not drink alcohol while using Celexa.</p>   <p> <span class="Bold">What are the possible side effects of Celexa? </span> </p>   <p> <span class="Bold">Celexa may cause serious side effects, including:</span> </p>   <p> <span class="Bold">See “<a href="#p01">What is the most important information I should know about Celexa?</a>”</span> </p>   <p>Common possible side effects in people who take Celexa include:</p>   <ul class="Disc">    <li>Nausea</li>    <li>Sleepiness</li>    <li>Weakness</li>    <li>Dizziness</li>    <li>Feeling anxious</li>    <li>Trouble sleeping</li>    <li>Sexual problems</li>    <li>Sweating</li>    <li>Shaking</li>    <li>Not feeling hungry</li>    <li>Dry mouth</li>    <li>Constipation</li>    <li>Diarrhea</li>    <li>Respiratory Infections</li>    <li>Yawning</li>   </ul>   <p>Other side effects in children and adolescents include:</p>   <ul class="Disc">    <li>increased thirst</li>    <li>abnormal increase in muscle movement or agitation</li>    <li>nose bleed</li>    <li>urinating more often</li>    <li>heavy menstrual periods</li>    <li>possible slowed growth rate and weight change. Your child's height and weight should be monitored during treatment with Celexa.</li>   </ul>   <p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Celexa. For more information, ask your healthcare provider or pharmacist.</p>   <p> <span class="Bold">CALL YOUR DOCTOR FOR MEDICAL ADVICE ABOUT SIDE EFFECTS. YOU MAY REPORT SIDE EFFECTS TO THE FDA AT 1-800-FDA-1088.</span> </p>   <p> <span class="Bold">How should I store Celexa?</span> </p>   <ul class="Disc">    <li>Store Celexa at 25&deg;C (77&deg;F), between 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</li>    <li>Keep Celexa bottle closed tightly.</li>   </ul>   <p> <span class="Bold">Keep Celexa and all medicines out of the reach of children.</span> </p>   <p> <span class="Bold">General information about Celexa</span> </p>   <p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Celexa for a condition for which it was not prescribed. Do not give Celexa to other people, even if they have the same condition. It may harm them.</p>   <p>This Medication Guide summarizes the most important information about Celexa. If you would like more information, talk with your healthcare provider. You may ask your healthcare provider or pharmacist for information about Celexa that is written for healthcare professionals.</p>   <p>For more information about Celexa call 1-800-678-1605 or go to www.Celexa.com.</p>   <p> <span class="Bold">What are the ingredients in Celexa?</span> </p>   <p>Active ingredient: citalopram hydrobromide</p>   <p>Inactive ingredients:</p>   <ul class="Disc">    <li> <span class="Bold">Tablets:</span> copolyvidone, corn starch, crosscarmellose sodium, glycerin, lactose monohydrate, magnesium stearate, hypromellose, microcrystalline cellulose, polyethylene glycol, titanium dioxide and iron dioxide for coloring.</li>   </ul>   <p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>   <p>Revised: July 2014</p>   <p>Distributed by:<br />Forest Pharmaceuticals, Inc.<br />Subsidiary of Forest Laboratories, Inc.<br />St. Louis, MO 63045 USA</p>   <p>Licensed from H. Lundbeck A/S</p>   <p>&copy; 2010, 2011, 2012, 2013, 2014 Forest Laboratories, Inc.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">Principal Display Panel – 10mg Bottle Label</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="s111"></a>  <a name="section-16"></a>   <p></p>    <p class="First">NDC 0456-4010-01</p>   <p> <span class="Bold">Celexa</span><span class="Sup">&reg;</span> citalopram HBr</p>   <p> <span class="Bold">Tablets-10 mg</span> </p>   <p>Equivalent to <span class="Bold">10 mg</span> citalopram</p>   <p> <span class="Bold">100 Tablets</span> </p>   <p> <span class="Bold">FOREST PHARMACEUTICALS, INC.<br /> </span>Subsidiary of Forest Laboratories, Inc. <br />St. Louis, Missouri 63045</p>   <div class="Figure">    <a name="f02"></a>   <img src="image.cfm?setid=4259d9b1-de34-43a4-85a8-41dd214e9177&name=cel00%2D0019%2D02%2Ejpg" alt="Principal Display Panel – 10mg Bottle Label" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">Principal Display Panel – 20mg Bottle Label</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="s112"></a>  <a name="section-17"></a>   <p></p>    <p class="First">NDC 0456-4020-01</p>   <p> <span class="Bold">Celexa</span><span class="Sup">&reg;</span> citalopram HBr</p>   <p> <span class="Bold">Tablets-20 mg</span> </p>   <p>Equivalent to <span class="Bold">20 mg</span> citalopram</p>   <p> <span class="Bold">100 Tablets</span> </p>   <p> <span class="Bold">FOREST PHARMACEUTICALS, INC.<br /> </span>Subsidiary of Forest Laboratories, Inc. <br />St. Louis, Missouri 63045</p>   <div class="Figure">    <a name="f03"></a>   <img src="image.cfm?setid=4259d9b1-de34-43a4-85a8-41dd214e9177&name=cel00%2D0019%2D03%2Ejpg" alt="Principal Display Panel – 20mg Bottle Label" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">Principal Display Panel – 40mg Bottle Label</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="s113"></a>  <a name="section-18"></a>   <p></p>    <p class="First">NDC 0456-4040-01</p>   <p> <span class="Bold">Celexa</span><span class="Sup">&reg;</span> citalopram HBr</p>   <p> <span class="Bold">Tablets-40 mg</span> </p>   <p>Equivalent to <span class="Bold">40 mg</span> citalopram</p>   <p> <span class="Bold">100 Tablets</span> </p>   <p> <span class="Bold">FOREST PHARMACEUTICALS, INC.<br /> </span>Subsidiary of Forest Laboratories, Inc. <br />St. Louis, Missouri 63045</p>   <div class="Figure">    <a name="f04"></a>   <img src="image.cfm?setid=4259d9b1-de34-43a4-85a8-41dd214e9177&name=cel00%2D0019%2D04%2Ejpg" alt="Principal Display Panel – 40mg Bottle Label" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">INGREDIENTS AND APPEARANCE</a> <div class="DataElementsTables toggle-content">   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>CELEXA&nbsp; </strong> <br /> <span class="contentTableReg">citalopram hydrobromide tablet, film coated</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:0456-4010</td>          </tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">ORAL</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>citalopram hydrobromide</strong> (UNII: I1E9D14F36) (citalopram - UNII:0DHU5B8D6V)</td>          <td class="formItem">citalopram</td>          <td class="formItem">10&nbsp;mg</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>copovidone</strong> (UNII: D9C330MD8B)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>starch, corn</strong> (UNII: O8232NY3SJ)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>croscarmellose sodium</strong> (UNII: M28OL1HH48)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>glycerin</strong> (UNII: PDC6A3C0OX)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>lactose monohydrate</strong> (UNII: EWQ57Q8I5X)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>magnesium stearate</strong> (UNII: 70097M6I30)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>hypromelloses</strong> (UNII: 3NXW29V3WO)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>cellulose, microcrystalline</strong> (UNII: OP1R32D61U)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>polyethylene glycols</strong> (UNII: 3WJQ0SDW1A)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>titanium dioxide</strong> (UNII: 15FIX9V2JP)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>FERRIC OXIDE RED</strong> (UNII: 1K09F3G675)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>FERRIC OXIDE YELLOW</strong> (UNII: EX438O2MRT)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Characteristics</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Color</td>          <td class="formItem">brown (beige)</td>          <td class="formLabel">Score</td>          <td class="formItem">no score</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Shape</td>          <td class="formItem">OVAL (Oval)</td>          <td class="formLabel">Size</td>          <td class="formItem">12mm</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Flavor</td>          <td class="formItem"></td>          <td class="formLabel">Imprint Code</td>          <td class="formItem">FP;10;MG</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Contains</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:0456-4010-01</td>          <td class="formItem">100 in 1 BOTTLE</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA020822</td>          <td class="formItem">07/17/1998</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>CELEXA&nbsp; </strong> <br /> <span class="contentTableReg">citalopram hydrobromide tablet, film coated</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:0456-4020</td>          </tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">ORAL</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>citalopram hydrobromide</strong> (UNII: I1E9D14F36) (citalopram - UNII:0DHU5B8D6V)</td>          <td class="formItem">citalopram</td>          <td class="formItem">20&nbsp;mg</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>copovidone</strong> (UNII: D9C330MD8B)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>starch, corn</strong> (UNII: O8232NY3SJ)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>croscarmellose sodium</strong> (UNII: M28OL1HH48)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>glycerin</strong> (UNII: PDC6A3C0OX)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>lactose monohydrate</strong> (UNII: EWQ57Q8I5X)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>magnesium stearate</strong> (UNII: 70097M6I30)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>hypromelloses</strong> (UNII: 3NXW29V3WO)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>cellulose, microcrystalline</strong> (UNII: OP1R32D61U)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>polyethylene glycols</strong> (UNII: 3WJQ0SDW1A)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>titanium dioxide</strong> (UNII: 15FIX9V2JP)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>FERRIC OXIDE RED</strong> (UNII: 1K09F3G675)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>FERRIC OXIDE YELLOW</strong> (UNII: EX438O2MRT)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Characteristics</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Color</td>          <td class="formItem">pink (pink)</td>          <td class="formLabel">Score</td>          <td class="formItem">2 pieces</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Shape</td>          <td class="formItem">OVAL (Oval)</td>          <td class="formLabel">Size</td>          <td class="formItem">12mm</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Flavor</td>          <td class="formItem"></td>          <td class="formLabel">Imprint Code</td>          <td class="formItem">F;P;20;MG</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Contains</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:0456-4020-01</td>          <td class="formItem">100 in 1 BOTTLE</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">2</th>          <td class="formItem">NDC:0456-4020-63</td>          <td class="formItem">10 in 1 BOX, UNIT-DOSE</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">2</th>          <td class="formItem">NDC:0456-4020-11</td>          <td class="formItem">10 in 1 BLISTER PACK</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA020822</td>          <td class="formItem">07/17/1998</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>CELEXA&nbsp; </strong> <br /> <span class="contentTableReg">citalopram hydrobromide tablet, film coated</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:0456-4040</td>          </tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">ORAL</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>citalopram hydrobromide</strong> (UNII: I1E9D14F36) (citalopram - UNII:0DHU5B8D6V)</td>          <td class="formItem">citalopram</td>          <td class="formItem">40&nbsp;mg</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>copovidone</strong> (UNII: D9C330MD8B)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>starch, corn</strong> (UNII: O8232NY3SJ)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>croscarmellose sodium</strong> (UNII: M28OL1HH48)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>glycerin</strong> (UNII: PDC6A3C0OX)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>lactose monohydrate</strong> (UNII: EWQ57Q8I5X)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>magnesium stearate</strong> (UNII: 70097M6I30)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>hypromelloses</strong> (UNII: 3NXW29V3WO)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>cellulose, microcrystalline</strong> (UNII: OP1R32D61U)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>polyethylene glycols</strong> (UNII: 3WJQ0SDW1A)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>titanium dioxide</strong> (UNII: 15FIX9V2JP)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Characteristics</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Color</td>          <td class="formItem">white (white)</td>          <td class="formLabel">Score</td>          <td class="formItem">2 pieces</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Shape</td>          <td class="formItem">OVAL (Oval)</td>          <td class="formLabel">Size</td>          <td class="formItem">12mm</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Flavor</td>          <td class="formItem"></td>          <td class="formLabel">Imprint Code</td>          <td class="formItem">F;P;40;MG</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Contains</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:0456-4040-01</td>          <td class="formItem">100 in 1 BOTTLE</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">2</th>          <td class="formItem">NDC:0456-4040-63</td>          <td class="formItem">10 in 1 BOX, UNIT-DOSE</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">2</th>          <td class="formItem">NDC:0456-4040-11</td>          <td class="formItem">10 in 1 BLISTER PACK</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA020822</td>          <td class="formItem">07/17/1998</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Labeler -&nbsp;</span>Forest Laboratories, Inc. (001288281) </td>      </tr>     </tbody>   </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Establishment</span></td>      </tr>      <tr>       <th class="formTitle" scope="col">Name</th>      <th class="formTitle" scope="col">Address</th>      <th class="formTitle" scope="col">ID/FEI</th>      <th class="formTitle" scope="col">Business Operations</th>      </tr>      <tr class="formTableRowAlt">       <td class="formItem">Forest Pharmaceuticals, Inc</td>      <td class="formItem"></td>      <td class="formItem">139645477</td>      <td class="formItem">PACK(0456-4010, 0456-4020, 0456-4040)</td>      </tr>     </tbody>   </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Establishment</span></td>      </tr>      <tr>       <th class="formTitle" scope="col">Name</th>      <th class="formTitle" scope="col">Address</th>      <th class="formTitle" scope="col">ID/FEI</th>      <th class="formTitle" scope="col">Business Operations</th>      </tr>      <tr class="formTableRowAlt">       <td class="formItem">H. Lundbeck A/S</td>      <td class="formItem"></td>      <td class="formItem">310613542</td>      <td class="formItem">API MANUFACTURE(0456-4010, 0456-4020, 0456-4040)</td>      </tr>     </tbody>   </table>  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li>                                            </ul>                                        <div class="control-nav">                                            <a class="open-all" href="#">View All Sections</a><a class="close-all" href="#">Close All Sections</a>                                        </div>                                        </div>                                    </div>                        </article>                       <div class="articlefooternav">                       <h2>Find additional resources</h2> <strong>(also available in the <a href="#leftmenu">left menu</a>)</strong>                                              <h3>Safety</h3>                       <p>                                                            <a href="#boxedwarning" target="_blank">Boxed Warnings</a>,                                                                                                                     <a href="/www.accessdata.fda.gov/scripts/medwatch/ " target="_blank">Report Adverse Events</a>,                                 <a href="http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety Recalls</a>,                                 <a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22citalopram%22+%29" target="_blank">Presence in Breast Milk</a>                                                   </p>                       <h3>Related Resources</h3>                       <p>                                                                                          <a href="http://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&query=citalopram" target="_blank">Medline Plus</a>,                                                       <a href="/www.clinicaltrials.gov/ct/search?submit=Search&term=citalopram" target="_blank">Clinical Trials</a>,                            <a href="#pubmed-menu" id="pubmed-bottom">PubMed</a>,                            <a href="http://www.drugbank.ca/search?utf8=%E2%9C%93&query=APRD00147&search_type=drugs&button=" target="_blank">Biochemical Data Summary</a>                                                  </p>                       <h3>More Info on this Drug</h3>                       <p>                            <a href="#modal-label-archives" class="modal-open">View Label Archives</a>,                             <a href="#modal-rx-norm" class="modal-open">RxNorm</a>,                             <a href="#modal-label-rss" class="modal-open">Get Label RSS Feed</a>                        </p>                    </div>                </div>                                <div class="divider"></div>            </div>        </div>        <!-- Label Archives Modal --><div class="mfp-hide modal" id="modal-label-archives">        <div class="modal-wrapper">        <header><h2>View Label Archives for this drug</h2></header>        <div class="top">        							    	    																																			    																	    	    	                             		       	                                                                                                           <h3 class="long-title">CELEXA- citalopram hydrobromide tablet, film coated <br></h3>            <h4>Number of versions: 11</h4>        </div>        <div class="modal-content">                <table class="modal">                    <tbody><tr>                        <th>Published Date</th>                        <th>Version</th>                               <th>Files</th>                    </tr>                                        <tr>                        <td>Jul 16, 2014</td>                        <td>							                                18                             							(current)                         </td>                              <td>                        								                                                            <a class="view-link" href="dailymed/drugInfo.cfm?setid=4259d9b1-de34-43a4-85a8-41dd214e9177" title="View this Label">view</a><span class="sep"> | </span>                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=145266">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Dec 20, 2013</td>                        <td>							                                17                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=127487">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Jul 11, 2013</td>                        <td>							                                16                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=113991">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Feb 26, 2013</td>                        <td>							                                15                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=101311">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Dec 13, 2012</td>                        <td>							                                13                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=95490">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Apr 13, 2012</td>                        <td>							                                12                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=77042">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Aug 29, 2011</td>                        <td>							                                9                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=62247">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Feb 10, 2009</td>                        <td>							                                8                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=10011">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Jan 7, 2009</td>                        <td>							                                3                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=9816">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Nov 14, 2008</td>                        <td>							                                2                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=9121">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Nov 30, 2007</td>                        <td>							                                1                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=6278">download</a>                                                    </td>                    </tr>                                    </tbody></table>        </div>        </div></div>        <!-- RxNorm Modal --><div class="mfp-hide modal" id="modal-rx-norm">        <div class="modal-wrapper">        <header><h2>RxNorm</h2></header>        <div class="top">            <h3 class="long-title">CELEXA- citalopram hydrobromide tablet, film coated <br></h3>        </div>        <div class="modal-content">        							    	    																																			    																	    	    	                             		       	                                                                                               			                            <table class="modal">                    <tbody><tr>                        <th></th>                        <th>RxCUI</th>                               <th>RxNorm NAME</th>                        <th>RxTTY</th>                    </tr>                                                                                                    <tr class="psn-rxtty">                                                                    <td>1</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=200371">200371</a></td>                              <td>citalopram 20 MG Oral Tablet</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>2</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=200371">200371</a></td>                              <td>Citalopram 20 MG Oral Tablet</td>                        <td>SCD</td>                    </tr>                   	                                                    <tr>                                                                    <td>3</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=200371">200371</a></td>                              <td>citalopram 20 MG (as citalopram hydrobromide 24.99 MG) Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>4</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=213344">213344</a></td>                              <td>CeleXA 20 MG Oral Tablet</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>5</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=213344">213344</a></td>                              <td>Citalopram 20 MG Oral Tablet [Celexa]</td>                        <td>SBD</td>                    </tr>                   	                                                    <tr>                                                                    <td>6</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=213344">213344</a></td>                              <td>Celexa 20 MG Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>7</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=213345">213345</a></td>                              <td>CeleXA 40 MG Oral Tablet</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>8</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=213345">213345</a></td>                              <td>Citalopram 40 MG Oral Tablet [Celexa]</td>                        <td>SBD</td>                    </tr>                   	                                                    <tr>                                                                    <td>9</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=213345">213345</a></td>                              <td>Celexa 40 MG Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>10</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=283672">283672</a></td>                              <td>citalopram 10 MG Oral Tablet</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>11</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=283672">283672</a></td>                              <td>Citalopram 10 MG Oral Tablet</td>                        <td>SCD</td>                    </tr>                   	                                                    <tr>                                                                    <td>12</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=283672">283672</a></td>                              <td>citalopram 10 MG (as citalopram hydrobromide 12.49 MG) Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>13</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=284591">284591</a></td>                              <td>CeleXA 10 MG Oral Tablet</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>14</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=284591">284591</a></td>                              <td>Citalopram 10 MG Oral Tablet [Celexa]</td>                        <td>SBD</td>                    </tr>                   	                                                    <tr>                                                                    <td>15</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=284591">284591</a></td>                              <td>Celexa 10 MG Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>16</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=309314">309314</a></td>                              <td>citalopram 40 MG Oral Tablet</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>17</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=309314">309314</a></td>                              <td>Citalopram 40 MG Oral Tablet</td>                        <td>SCD</td>                    </tr>                   	                                                    <tr>                                                                    <td>18</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=309314">309314</a></td>                              <td>citalopram 40 MG (as citalopram hydrobromide 49.98 MG) Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                </tbody></table>                    </div>        </div></div><!-- Label RSS Modal --><div class="mfp-hide modal" id="modal-label-rss">        <header><h2>Get Label RSS Feed for this Drug</h2></header>        <div class="top">            <h3 class="long-title">CELEXA- citalopram hydrobromide tablet, film coated <br></h3>        </div>        <div class="modal-content">            <h4>To receive this label RSS feed</h4>            <p>Copy the URL below and paste it into your RSS Reader application.			<p><a href="https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=4259d9b1-de34-43a4-85a8-41dd214e9177" target="_blank">https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=4259d9b1-de34-43a4-85a8-41dd214e9177</a></p>            <h4>To receive all DailyMed Updates for the last seven days</h4>            <p>Copy the URL below and paste it into your RSS Reader application.</p>            <p><a href="https://dailymed.nlm.nih.gov/dailymed/rss.cfm" target="_blank">https://dailymed.nlm.nih.gov/dailymed/rss.cfm</a></p>            <h4>What will I get with the DailyMed RSS feed?</h4>            <p>DailyMed will deliver notification of updates and additions to Drug Label information currently shown on this site through its RSS feed.</p>            <p>DailyMed will deliver this notification to your desktop, Web browser, or e-mail depending on the RSS Reader you select to use. To view updated drug label links, paste the RSS feed address (URL) shown below into a RSS reader, or use a browser which supports RSS feeds, such as Safari for Mac OS X.</p>            <h4>How to discontinue the RSS feed</h4>            <p>If you no longer wish to have this DailyMed RSS service, simply delete the copied URL from your RSS Reader.</p>            <a href="dailymed/rss-updates.cfm" class="rss-icon"></a> <a href="dailymed/rss-updates.cfm">More about getting RSS News & Updates from DailyMed</a>        </div></div>    <!-- this div is only for jQuery --><div class="search-results">    <div class="filter-drop"></div></div><div class="webview"></div><div class="hide-on-mobile"></div>    <div class="mobilenav no-js">        <ul>            <li><a href="dailymed/index.cfm">Home</a></li>            <li>News                <ul>                    <li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>                    <li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>                </ul>            </li>            <li>Search                <ul>                    <li><a href="dailymed/advanced-search.cfm">Advanced Search</a></li>                    	                    <li><a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>	                    <li><a href="dailymed/archives/index.cfm">Labels Archives</a></li>                                                            <li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID Tool</a></li>                </ul>            </li>                            <li><a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a></li>                <li>NLM SPL Resources                    <ul>                        <li><a href="dailymed/spl-resources.cfm">Download Data</a>                            <ul>                                <li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>                                <li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Index Files</a></li>                                <li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>                            </ul>                        </li>                        <li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>                        <li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>                    </ul>                </li>                <li>Application Development Support                    <ul>                        <li><a href="dailymed/app-support.cfm">Resources</a>                            <ul>                                <li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>                                <li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>                            </ul>                        </li>                    </ul>                </li>                        <li><a href="dailymed/help.cfm">Help</a></li>                                </ul>    </div>    <footer class="mainFooter">        <div class="container">            <div class="three columns">             <div class="nihnlmlogoprint"><img src="/dailymed/images/nihnlmlogoprint.png" alt="NIH NLM Logo"></div>                <a href="/www.nlm.nih.gov/" class="logo" title="National Library of Medicine | National Institutes of Health"><img src="/dailymed/images/footer-logo.png" width="109" height="37" alt="National Library of Medicine | National Institutes of Health" title="National Library of Medicine | National Institutes of Health" /></a>            </div>                        <div id="share" class="thirteen columns">                <div class="footer-links">                    <ul class="primary">                        <li><a href="dailymed/about-dailymed.cfm" title="About DailyMed">About DailyMed</a><span>|</span></li>                        <li><a href="dailymed/contact-us.cfm" title="Contact Us">Contact Us</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/copyright.html" title="Copyright" target="_blank" rel="bookmark">Copyright</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/privacy.html" title="Privacy" target="_blank" rel="bookmark">Privacy</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/accessibility.html" title="Web Accessibility" target="_blank" rel="bookmark">Web Accessibility</a><span>|</span></li>                        <li><a href="/www.hon.ch/HONcode/Conduct.html?HONConduct393117" target="_blank" title="HONCode Certification">DailyMed is HONCode Certified</a></li>                    </ul>                    <ul class="secondary">                        <li><a href="http://www.nih.gov/" title="National Institutes of Health" target="_blank" rel="bookmark">National Institutes of Health</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/" title="U.S. National Library of Medicine" target="_blank" rel="bookmark">U.S. National Library of Medicine</a><span>|</span></li>                        <li><a href="http://www.hhs.gov/" title="Health &amp; Human Services" target="_blank" rel="bookmark">Health &amp; Human Services</a></li>                    </ul>                    <ul class="secondary mobile">                        <li><a href="http://www.nih.gov/" title="National Institutes of Health" target="_blank" rel="bookmark">NIH</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/" title="U.S. National Library of Medicine" target="_blank" rel="bookmark">NLM</a><span>|</span></li>                        <li><a href="http://www.hhs.gov/" title="Health &amp; Human Services" target="_blank" rel="bookmark">Health &amp; Human Services</a></li>                    </ul>                    <div class="social">                        Share                         <!-- AddThis Button BEGIN -->                        <noscript>: JavaScript needed for Sharing tools</noscript>                        <div class="addthis_toolbox addthis_default_style addthis_16x16_style">							                                                            	                                	            			        	                                                            <a class="email-share" href="mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0ACELEXA%2D%20Citalopram%20Hydrobromide%20Tablet%2C%20Film%20Coated%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3D4259d9b1%2Dde34%2D43a4%2D85a8%2D41dd214e9177%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E" title="Share by Email"></a>                            <a class="addthis_button_facebook"></a>                            <a class="addthis_button_twitter"></a>                            <a class="at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share" href="/www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed" target="_blank" style="width: 16px; height: 16px">                                <span style="left: -9999px; position: absolute;">Bookmark &amp; Share</span>                                <img style="width:17px; margin-top: -2px;" src="/dailymed/images/addthis-image.jpg" alt="Bookmark &amp; Share">                            </a>                        </div>                                                <!-- AddThis Button END -->                    </div>                                    </div>            </div>        </div>                <div class="divider"></div>    </footer>    <div class="divider"></div></div><div class="to-top"></div><!-- this div is only for jQuery --><div class="search-results">    <div class="filter-drop"></div></div><div class="webview"></div> <div class="hide-on-mobile"></div><!-- START OF SmartSource Data Collector TAG --><!-- Copyright (c) 1996-2012 Webtrends Inc.  All rights reserved. --><!-- Version: 9.4.0 --><!-- Tag Builder Version: 3.3  --><!-- Created: 1/25/2012 11:57:33 PM --><script type="text/javascript" src="/dailymed/scripts/webtrends.min.js"></script><!-- ----------------------------------------------------------------------------------- --><!-- Warning: The two script blocks below must remain inline. Moving them to an external --><!-- JavaScript include file can cause serious problems with cross-domain tracking.      --><!-- ----------------------------------------------------------------------------------- --><script type="text/javascript">//<![CDATA[var _tag=new WebTrends();_tag.dcsGetId();//]]></script><script type="text/javascript">//<![CDATA[_tag.dcsCustom=function(){// Add custom parameters here.//_tag.DCSext.param_name=param_value;_tag.DCSext.dcsid=_tag.dcsid}_tag.trackAllEvents=true;_tag.dcsCollect();//]]></script><noscript><div><img alt="DCSIMG" id="DCSIMG" width="1" height="1" src="//wtsdc.nlm.nih.gov/dcsm7fmt310000o265ioub7ib_2b7v/njs.gif?dcsuri=/nojavascript&amp;WT.js=No&amp;WT.tv=9.4.0&amp;dcssip=dailymed.nlm.nih.gov&amp;dcsid=dcsm7fmt310000o265ioub7ib_2b7v"/></div></noscript><!-- END OF SmartSource Data Collector TAG --><script type="text/javascript">    setTimeout(function(){var a=document.createElement("script");    var b=document.getElementsByTagName("script")[0];    a.src=document.location.protocol+"//dnn506yrbagrg.cloudfront.net/pages/scripts/0027/2050.js?"+Math.floor(new Date().getTime()/3600000);    a.async=true;a.type="text/javascript";b.parentNode.insertBefore(a,b)}, 1);</script><script type="text/javascript">    function getParameterByName(name) {        name = name.replace(/[\[]/, "\\[").replace(/[\]]/, "\\]");        var regex = new RegExp("[\\?&]" + name + "=([^&#]*)"),            results = regex.exec(location.search);        return results === null ? "" : decodeURIComponent(results[1].replace(/\+/g, " "));    }    /* Tracking label type on search pages */    function CE_READY() {        if(!getParameterByName('labeltype')){           CE2.set(1, "No Label Type");        }        else{            var labeltype = getParameterByName('labeltype');            if(labeltype == 'all'){                CE2.set(1, "All");            }            else if(labeltype == 'human'){                CE2.set(1, "Human");            }            else if(labeltype == 'animal'){                CE2.set(1, "Animal");            }            else{                CE2.set(1, "Unknown");            }        }    }</script>                    <!-- DAP Universal Analytics -->    <script language="javascript" id="_fed_an_ua_tag" src="/dailymed/scripts/Universal-Federated-Analytics-Min.2.0.js?agency=HHS&subagency=NIH&enhlink=true&dclink=true"></script>    <script src="/dailymed/scripts/preview-text.min.js"></script></body></html>    